Unnamed: 0,GENE,MUTATION_REMARK,GENOMIC_MUTATION_ID,FUSION_ID,MUTATION_AA_SYNTAX,DISEASE,ACTIONABILITY_RANK,DEVELOPMENT_STATUS,DRUG_COMBINATION,TESTING_REQUIRED,TRIAL_STATUS,TRIAL_ID,TRIAL_NAME,COMPLETION_STATUS,TRIAL_PRIMARY_COMPLETION_DATE,PATIENT_PRESCREENING,RESULTS_AVAILABILITY,PROGRESSION_REMARK,SOURCE_TYPE,SOURCE,TREATMENT_HISTORY,PATIENT_AGE,PRIMARY_OUTCOME_MEASURE,NUMBER_OF_PATIENTS,TREATED_NUMBER,CONTROL_NUMBER,CONTROL_TREATMENT,ORR_TREAT,ORR_CON,ORR_CI,ORR_PVAL,DOR_TREAT,DOR_CON,DOR_CI,DOR_PVAL,PFS_TREAT,PFS_CON,PFS_HR,PFS_CI,PFS_PVAL,TTP_TREAT,TTP_CON,TTP_HR,TTP_CI,TTP_PVAL,DCR_TREAT,DCR_CON,DCR_PVAL,OS_TREAT,OS_CON,OS_HR,OS_CI,OS_PVAL,OBJ_RR_TREAT,CR_COUNT,PR_COUNT,SD_COUNT,RFS_TREAT,RFS_CON,RFS_HR,RFS_CI,RFS_PVAL,BLOOD_RESPONSE,RESPONSE_VALUE,TIMEPOINT,CLASSIFICATION_ID,LAST_UPDATED,COSMIC_PHENOTYPE_ID,SITE_PRIMARY_COSMIC,SITE_SUBTYPE1_COSMIC,SITE_SUBTYPE2_COSMIC,SITE_SUBTYPE3_COSMIC,HISTOLOGY_COSMIC,HIST_SUBTYPE1_COSMIC,HIST_SUBTYPE2_COSMIC,HIST_SUBTYPE3_COSMIC
12155.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Bevacizumab,,Completed,NCT00109070,,,,No,Yes,Response not correlated with mutation status,1.0,19144677,Untreated,,Unknown,230.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12156.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Bevacizumab,,Completed,NCT00109070,,,,No,Yes,Response not correlated with mutation status,1.0,19144677,Untreated,,Unknown,230.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12157.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Bevacizumab,,Completed,NCT00109070,,,,No,Yes,Response not correlated with mutation status,1.0,19144677,Untreated,,Unknown,230.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12158.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Bevacizumab,,Completed,NCT00109070,,,,No,Yes,Response not correlated with mutation status,1.0,19144677,Untreated,,Unknown,230.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12159.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Bevacizumab,,Completed,NCT00109070,,,,No,Yes,Response not correlated with mutation status,1.0,19144677,Untreated,,Unknown,230.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12160.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Bevacizumab,,Completed,NCT00109070,,,,No,Yes,Response not correlated with mutation status,1.0,19144677,Untreated,,Unknown,230.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12161.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Bevacizumab,,Completed,NCT00109070,,,,No,Yes,Response not correlated with mutation status,1.0,19144677,Untreated,,Unknown,230.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12162.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Bevacizumab,,Completed,NCT00109070,,,,No,Yes,Response not correlated with mutation status,1.0,19144677,Untreated,,Unknown,230.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12163.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Bevacizumab,,Completed,NCT00109070,,,,No,Yes,Response not correlated with mutation status,1.0,19144677,Untreated,,Unknown,230.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12164.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Bevacizumab,,Completed,NCT00109070,,,,No,Yes,Response not correlated with mutation status,1.0,19144677,Untreated,,Unknown,230.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12165.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Bevacizumab,,Completed,NCT00109070,,,,No,Yes,Response not correlated with mutation status,1.0,19144677,Untreated,,Unknown,230.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12166.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Bevacizumab,,Completed,NCT00109070,,,,No,Yes,Response not correlated with mutation status,1.0,19144677,Untreated,,Unknown,230.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12167.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Bevacizumab,,Completed,NCT00109070,,,,No,Yes,Response not correlated with mutation status,1.0,19144677,Untreated,,Unknown,230.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12168.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Bevacizumab,,Completed,NCT00109070,,,,No,Yes,Response not correlated with mutation status,1.0,19144677,Untreated,,Unknown,230.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12169.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Bevacizumab,,Completed,NCT00109070,,,,No,Yes,Response not correlated with mutation status,1.0,19144677,Untreated,,Unknown,230.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12170.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Bevacizumab,,Completed,NCT00109070,,,,No,Yes,Response not correlated with mutation status,1.0,19144677,Untreated,,Unknown,230.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12171.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Bevacizumab,,Completed,NCT00109070,,,,No,Yes,Response not correlated with mutation status,1.0,19144677,Untreated,,Unknown,230.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12172.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Bevacizumab,,Completed,NCT00109070,,,,No,Yes,Response not correlated with mutation status,1.0,19144677,Untreated,,Unknown,230.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12173.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Bevacizumab,,Completed,NCT00109070,,,,No,Yes,Response not correlated with mutation status,1.0,19144677,Untreated,,Unknown,230.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12174.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Bevacizumab,,Completed,NCT00109070,,,,No,Yes,Response not correlated with mutation status,1.0,19144677,Untreated,,Unknown,230.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12175.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Bevacizumab,,Completed,NCT00109070,,,,No,Yes,Response not correlated with mutation status,1.0,19144677,Untreated,,Unknown,230.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12176.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Bevacizumab,,Completed,NCT00109070,,,,No,Yes,Response not correlated with mutation status,1.0,19144677,Untreated,,Unknown,230.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12177.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Bevacizumab,,Completed,NCT00109070,,,,No,Yes,Response not correlated with mutation status,1.0,19144677,Untreated,,Unknown,230.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12178.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Bevacizumab,,Completed,NCT00109070,,,,No,Yes,Response not correlated with mutation status,1.0,19144677,Untreated,,Unknown,230.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12179.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Bevacizumab,,Completed,NCT00109070,,,,No,Yes,Response not correlated with mutation status,1.0,19144677,Untreated,,Unknown,230.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12180.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Bevacizumab,,Completed,NCT00109070,,,,No,Yes,Response not correlated with mutation status,1.0,19144677,Untreated,,Unknown,230.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12181.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Bevacizumab,,Completed,NCT00109070,,,,No,Yes,Response not correlated with mutation status,1.0,19144677,Untreated,,Unknown,230.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12182.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Bevacizumab,,Completed,NCT00109070,,,,No,Yes,Response not correlated with mutation status,1.0,19144677,Untreated,,Unknown,230.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12183.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Bevacizumab,,Completed,NCT00109070,,,,No,Yes,Response not correlated with mutation status,1.0,19144677,Untreated,,Unknown,230.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12184.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Bevacizumab,,Completed,NCT00109070,,,,No,Yes,Response not correlated with mutation status,1.0,19144677,Untreated,,Unknown,230.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12185.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Bevacizumab,,Completed,NCT00109070,,,,No,Yes,Response not correlated with mutation status,1.0,19144677,Untreated,,Unknown,230.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12186.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Bevacizumab,,Completed,NCT00109070,,,,No,Yes,Response not correlated with mutation status,1.0,19144677,Untreated,,Unknown,230.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12187.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Bevacizumab,,Completed,NCT00109070,,,,No,Yes,Response not correlated with mutation status,1.0,19144677,Untreated,,Unknown,230.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12188.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Bevacizumab,,Completed,NCT00109070,,,,No,Yes,Response not correlated with mutation status,1.0,19144677,Untreated,,Unknown,230.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12189.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Bevacizumab,,Completed,NCT00109070,,,,No,Yes,Response not correlated with mutation status,1.0,19144677,Untreated,,Unknown,230.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12190.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Bevacizumab,,Completed,NCT00109070,,,,No,Yes,Response not correlated with mutation status,1.0,19144677,Untreated,,Unknown,230.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12191.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Bevacizumab,,Completed,NCT00109070,,,,No,Yes,Response not correlated with mutation status,1.0,19144677,Untreated,,Unknown,230.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12192.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Bevacizumab,,Completed,NCT00109070,,,,No,Yes,Response not correlated with mutation status,1.0,19144677,Untreated,,Unknown,230.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12193.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Bevacizumab,,Completed,NCT00109070,,,,No,Yes,Response not correlated with mutation status,1.0,19144677,Untreated,,Unknown,230.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12194.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Bevacizumab,,Completed,NCT00109070,,,,No,Yes,Response not correlated with mutation status,1.0,19144677,Untreated,,Unknown,230.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12195.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Bevacizumab,,Completed,NCT00109070,,,,No,Yes,Response not correlated with mutation status,1.0,19144677,Untreated,,Unknown,230.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12196.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Bevacizumab,,Completed,NCT00109070,,,,No,Yes,Response not correlated with mutation status,1.0,19144677,Untreated,,Unknown,230.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12197.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Bevacizumab,,Completed,NCT00109070,,,,No,Yes,Response not correlated with mutation status,1.0,19144677,Untreated,,Unknown,230.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12198.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Bevacizumab,,Completed,NCT00109070,,,,No,Yes,Response not correlated with mutation status,1.0,19144677,Untreated,,Unknown,230.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12199.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Bevacizumab,,Completed,NCT00109070,,,,No,Yes,Response not correlated with mutation status,1.0,19144677,Untreated,,Unknown,230.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12200.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Bevacizumab,,Completed,NCT00109070,,,,No,Yes,Response not correlated with mutation status,1.0,19144677,Untreated,,Unknown,230.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12201.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Bevacizumab,,Completed,NCT00109070,,,,No,Yes,Response not correlated with mutation status,1.0,19144677,Untreated,,Unknown,230.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12202.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Bevacizumab,,Completed,NCT00109070,,,,No,Yes,Response not correlated with mutation status,1.0,19144677,Untreated,,Unknown,230.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12203.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Bevacizumab,,Completed,NCT00109070,,,,No,Yes,Response not correlated with mutation status,1.0,19144677,Untreated,,Unknown,230.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12204.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Bevacizumab,,Completed,NCT00109070,,,,No,Yes,Response not correlated with mutation status,1.0,19144677,Untreated,,Unknown,230.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12205.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Bevacizumab,,Completed,NCT00109070,,,,No,Yes,Response not correlated with mutation status,1.0,19144677,Untreated,,Unknown,230.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12206.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Bevacizumab,,Completed,NCT00109070,,,,No,Yes,Response not correlated with mutation status,1.0,19144677,Untreated,,Unknown,230.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12207.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Bevacizumab,,Completed,NCT00109070,,,,No,Yes,Response not correlated with mutation status,1.0,19144677,Untreated,,Unknown,230.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12208.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Bevacizumab,,Completed,NCT00109070,,,,No,Yes,Response not correlated with mutation status,1.0,19144677,Untreated,,Unknown,230.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12209.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Bevacizumab,,Completed,NCT00109070,,,,No,Yes,Response not correlated with mutation status,1.0,19144677,Untreated,,Unknown,230.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12265.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 4,Bevacizumab,,Unknown,,,,,Yes,Yes,Response not correlated with mutation status,1.0,29085005,,,Unknown,141.0,141.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12266.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 4,Bevacizumab,,Unknown,,,,,Yes,Yes,Response not correlated with mutation status,1.0,29085005,,,Unknown,141.0,141.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12267.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 4,Bevacizumab,,Unknown,,,,,Yes,Yes,Response not correlated with mutation status,1.0,29085005,,,Unknown,141.0,141.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12268.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 4,Bevacizumab,,Unknown,,,,,Yes,Yes,Response not correlated with mutation status,1.0,29085005,,,Unknown,141.0,141.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12269.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 4,Bevacizumab,,Unknown,,,,,Yes,Yes,Response not correlated with mutation status,1.0,29085005,,,Unknown,141.0,141.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12270.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 4,Bevacizumab,,Unknown,,,,,Yes,Yes,Response not correlated with mutation status,1.0,29085005,,,Unknown,141.0,141.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12271.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 4,Bevacizumab,,Unknown,,,,,Yes,Yes,Response not correlated with mutation status,1.0,29085005,,,Unknown,141.0,141.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12272.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 4,Bevacizumab,,Unknown,,,,,Yes,Yes,Response not correlated with mutation status,1.0,29085005,,,Unknown,141.0,141.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12273.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 4,Bevacizumab,,Unknown,,,,,Yes,Yes,Response not correlated with mutation status,1.0,29085005,,,Unknown,141.0,141.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12274.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 4,Bevacizumab,,Unknown,,,,,Yes,Yes,Response not correlated with mutation status,1.0,29085005,,,Unknown,141.0,141.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12275.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 4,Bevacizumab,,Unknown,,,,,Yes,Yes,Response not correlated with mutation status,1.0,29085005,,,Unknown,141.0,141.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12276.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 4,Bevacizumab,,Unknown,,,,,Yes,Yes,Response not correlated with mutation status,1.0,29085005,,,Unknown,141.0,141.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12277.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 4,Bevacizumab,,Unknown,,,,,Yes,Yes,Response not correlated with mutation status,1.0,29085005,,,Unknown,141.0,141.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12278.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 4,Bevacizumab,,Unknown,,,,,Yes,Yes,Response not correlated with mutation status,1.0,29085005,,,Unknown,141.0,141.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12279.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 4,Bevacizumab,,Unknown,,,,,Yes,Yes,Response not correlated with mutation status,1.0,29085005,,,Unknown,141.0,141.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12280.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 4,Bevacizumab,,Unknown,,,,,Yes,Yes,Response not correlated with mutation status,1.0,29085005,,,Unknown,141.0,141.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12281.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 4,Bevacizumab,,Unknown,,,,,Yes,Yes,Response not correlated with mutation status,1.0,29085005,,,Unknown,141.0,141.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12282.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 4,Bevacizumab,,Unknown,,,,,Yes,Yes,Response not correlated with mutation status,1.0,29085005,,,Unknown,141.0,141.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12283.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 4,Bevacizumab,,Unknown,,,,,Yes,Yes,Response not correlated with mutation status,1.0,29085005,,,Unknown,141.0,141.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12284.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 4,Bevacizumab,,Unknown,,,,,Yes,Yes,Response not correlated with mutation status,1.0,29085005,,,Unknown,141.0,141.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12285.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 4,Bevacizumab,,Unknown,,,,,Yes,Yes,Response not correlated with mutation status,1.0,29085005,,,Unknown,141.0,141.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12286.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 4,Bevacizumab,,Unknown,,,,,Yes,Yes,Response not correlated with mutation status,1.0,29085005,,,Unknown,141.0,141.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12287.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 4,Bevacizumab,,Unknown,,,,,Yes,Yes,Response not correlated with mutation status,1.0,29085005,,,Unknown,141.0,141.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12288.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 4,Bevacizumab,,Unknown,,,,,Yes,Yes,Response not correlated with mutation status,1.0,29085005,,,Unknown,141.0,141.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12289.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 4,Bevacizumab,,Unknown,,,,,Yes,Yes,Response not correlated with mutation status,1.0,29085005,,,Unknown,141.0,141.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12290.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 4,Bevacizumab,,Unknown,,,,,Yes,Yes,Response not correlated with mutation status,1.0,29085005,,,Unknown,141.0,141.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12291.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 4,Bevacizumab,,Unknown,,,,,Yes,Yes,Response not correlated with mutation status,1.0,29085005,,,Unknown,141.0,141.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12292.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 4,Bevacizumab,,Unknown,,,,,Yes,Yes,Response not correlated with mutation status,1.0,29085005,,,Unknown,141.0,141.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12293.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 4,Bevacizumab,,Unknown,,,,,Yes,Yes,Response not correlated with mutation status,1.0,29085005,,,Unknown,141.0,141.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12294.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 4,Bevacizumab,,Unknown,,,,,Yes,Yes,Response not correlated with mutation status,1.0,29085005,,,Unknown,141.0,141.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12295.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 4,Bevacizumab,,Unknown,,,,,Yes,Yes,Response not correlated with mutation status,1.0,29085005,,,Unknown,141.0,141.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12296.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 4,Bevacizumab,,Unknown,,,,,Yes,Yes,Response not correlated with mutation status,1.0,29085005,,,Unknown,141.0,141.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12297.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 4,Bevacizumab,,Unknown,,,,,Yes,Yes,Response not correlated with mutation status,1.0,29085005,,,Unknown,141.0,141.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12298.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 4,Bevacizumab,,Unknown,,,,,Yes,Yes,Response not correlated with mutation status,1.0,29085005,,,Unknown,141.0,141.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12299.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 4,Bevacizumab,,Unknown,,,,,Yes,Yes,Response not correlated with mutation status,1.0,29085005,,,Unknown,141.0,141.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12300.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 4,Bevacizumab,,Unknown,,,,,Yes,Yes,Response not correlated with mutation status,1.0,29085005,,,Unknown,141.0,141.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12301.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 4,Bevacizumab,,Unknown,,,,,Yes,Yes,Response not correlated with mutation status,1.0,29085005,,,Unknown,141.0,141.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12302.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 4,Bevacizumab,,Unknown,,,,,Yes,Yes,Response not correlated with mutation status,1.0,29085005,,,Unknown,141.0,141.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12303.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 4,Bevacizumab,,Unknown,,,,,Yes,Yes,Response not correlated with mutation status,1.0,29085005,,,Unknown,141.0,141.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12304.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 4,Bevacizumab,,Unknown,,,,,Yes,Yes,Response not correlated with mutation status,1.0,29085005,,,Unknown,141.0,141.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12305.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 4,Bevacizumab,,Unknown,,,,,Yes,Yes,Response not correlated with mutation status,1.0,29085005,,,Unknown,141.0,141.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12306.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 4,Bevacizumab,,Unknown,,,,,Yes,Yes,Response not correlated with mutation status,1.0,29085005,,,Unknown,141.0,141.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12307.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 4,Bevacizumab,,Unknown,,,,,Yes,Yes,Response not correlated with mutation status,1.0,29085005,,,Unknown,141.0,141.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12308.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 4,Bevacizumab,,Unknown,,,,,Yes,Yes,Response not correlated with mutation status,1.0,29085005,,,Unknown,141.0,141.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12309.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 4,Bevacizumab,,Unknown,,,,,Yes,Yes,Response not correlated with mutation status,1.0,29085005,,,Unknown,141.0,141.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12310.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 4,Bevacizumab,,Unknown,,,,,Yes,Yes,Response not correlated with mutation status,1.0,29085005,,,Unknown,141.0,141.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12311.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 4,Bevacizumab,,Unknown,,,,,Yes,Yes,Response not correlated with mutation status,1.0,29085005,,,Unknown,141.0,141.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12312.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 4,Bevacizumab,,Unknown,,,,,Yes,Yes,Response not correlated with mutation status,1.0,29085005,,,Unknown,141.0,141.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12313.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 4,Bevacizumab,,Unknown,,,,,Yes,Yes,Response not correlated with mutation status,1.0,29085005,,,Unknown,141.0,141.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12314.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 4,Bevacizumab,,Unknown,,,,,Yes,Yes,Response not correlated with mutation status,1.0,29085005,,,Unknown,141.0,141.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12315.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 4,Bevacizumab,,Unknown,,,,,Yes,Yes,Response not correlated with mutation status,1.0,29085005,,,Unknown,141.0,141.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12316.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 4,Bevacizumab,,Unknown,,,,,Yes,Yes,Response not correlated with mutation status,1.0,29085005,,,Unknown,141.0,141.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12317.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 4,Bevacizumab,,Unknown,,,,,Yes,Yes,Response not correlated with mutation status,1.0,29085005,,,Unknown,141.0,141.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12318.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 4,Bevacizumab,,Unknown,,,,,Yes,Yes,Response not correlated with mutation status,1.0,29085005,,,Unknown,141.0,141.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12319.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 4,Bevacizumab,,Unknown,,,,,Yes,Yes,Response not correlated with mutation status,1.0,29085005,,,Unknown,141.0,141.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
220.0,ALK,ALK_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Ceritinib,,Terminated,NCT02638909,,PCD,2018Mar29,Yes,Yes,Slow accrual,4.0,NCT02638909,,,"Disease control rate, Clinical benefit rate",0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
221.0,ALK,ALK_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Ceritinib,,Terminated,NCT02638909,,PCD,2018Mar29,Yes,Yes,Slow accrual,4.0,NCT02638909,,,"Disease control rate, Clinical benefit rate",0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
222.0,ALK,ALK_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Ceritinib,,Terminated,NCT02638909,,PCD,2018Mar29,Yes,Yes,Slow accrual,4.0,NCT02638909,,,"Disease control rate, Clinical benefit rate",0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
223.0,ALK,ALK_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Ceritinib,,Terminated,NCT02638909,,PCD,2018Mar29,Yes,Yes,Slow accrual,4.0,NCT02638909,,,"Disease control rate, Clinical benefit rate",0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
224.0,ALK,ALK_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Ceritinib,,Terminated,NCT02638909,,PCD,2018Mar29,Yes,Yes,Slow accrual,4.0,NCT02638909,,,"Disease control rate, Clinical benefit rate",0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
225.0,ALK,ALK_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Ceritinib,,Terminated,NCT02638909,,PCD,2018Mar29,Yes,Yes,Slow accrual,4.0,NCT02638909,,,"Disease control rate, Clinical benefit rate",0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
226.0,ALK,ALK_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Ceritinib,,Terminated,NCT02638909,,PCD,2018Mar29,Yes,Yes,Slow accrual,4.0,NCT02638909,,,"Disease control rate, Clinical benefit rate",0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
227.0,ALK,ALK_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Ceritinib,,Terminated,NCT02638909,,PCD,2018Mar29,Yes,Yes,Slow accrual,4.0,NCT02638909,,,"Disease control rate, Clinical benefit rate",0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
228.0,ALK,ALK_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Ceritinib,,Terminated,NCT02638909,,PCD,2018Mar29,Yes,Yes,Slow accrual,4.0,NCT02638909,,,"Disease control rate, Clinical benefit rate",0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
229.0,ALK,ALK_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Ceritinib,,Terminated,NCT02638909,,PCD,2018Mar29,Yes,Yes,Slow accrual,4.0,NCT02638909,,,"Disease control rate, Clinical benefit rate",0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
230.0,ALK,ALK_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Ceritinib,,Terminated,NCT02638909,,PCD,2018Mar29,Yes,Yes,Slow accrual,4.0,NCT02638909,,,"Disease control rate, Clinical benefit rate",0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
231.0,ALK,ALK_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Ceritinib,,Terminated,NCT02638909,,PCD,2018Mar29,Yes,Yes,Slow accrual,4.0,NCT02638909,,,"Disease control rate, Clinical benefit rate",0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
232.0,ALK,ALK_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Ceritinib,,Terminated,NCT02638909,,PCD,2018Mar29,Yes,Yes,Slow accrual,4.0,NCT02638909,,,"Disease control rate, Clinical benefit rate",0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
233.0,ALK,ALK_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Ceritinib,,Terminated,NCT02638909,,PCD,2018Mar29,Yes,Yes,Slow accrual,4.0,NCT02638909,,,"Disease control rate, Clinical benefit rate",0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
234.0,ALK,ALK_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Ceritinib,,Terminated,NCT02638909,,PCD,2018Mar29,Yes,Yes,Slow accrual,4.0,NCT02638909,,,"Disease control rate, Clinical benefit rate",0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
235.0,ALK,ALK_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Ceritinib,,Terminated,NCT02638909,,PCD,2018Mar29,Yes,Yes,Slow accrual,4.0,NCT02638909,,,"Disease control rate, Clinical benefit rate",0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
236.0,ALK,ALK_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Ceritinib,,Terminated,NCT02638909,,PCD,2018Mar29,Yes,Yes,Slow accrual,4.0,NCT02638909,,,"Disease control rate, Clinical benefit rate",0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
237.0,ALK,ALK_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Ceritinib,,Terminated,NCT02638909,,PCD,2018Mar29,Yes,Yes,Slow accrual,4.0,NCT02638909,,,"Disease control rate, Clinical benefit rate",0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
238.0,ALK,ALK_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Ceritinib,,Terminated,NCT02638909,,PCD,2018Mar29,Yes,Yes,Slow accrual,4.0,NCT02638909,,,"Disease control rate, Clinical benefit rate",0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
239.0,ALK,ALK_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Ceritinib,,Terminated,NCT02638909,,PCD,2018Mar29,Yes,Yes,Slow accrual,4.0,NCT02638909,,,"Disease control rate, Clinical benefit rate",0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
240.0,ALK,ALK_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Ceritinib,,Terminated,NCT02638909,,PCD,2018Mar29,Yes,Yes,Slow accrual,4.0,NCT02638909,,,"Disease control rate, Clinical benefit rate",0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
241.0,ALK,ALK_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Ceritinib,,Terminated,NCT02638909,,PCD,2018Mar29,Yes,Yes,Slow accrual,4.0,NCT02638909,,,"Disease control rate, Clinical benefit rate",0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
242.0,ALK,ALK_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Ceritinib,,Terminated,NCT02638909,,PCD,2018Mar29,Yes,Yes,Slow accrual,4.0,NCT02638909,,,"Disease control rate, Clinical benefit rate",0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
243.0,ALK,ALK_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Ceritinib,,Terminated,NCT02638909,,PCD,2018Mar29,Yes,Yes,Slow accrual,4.0,NCT02638909,,,"Disease control rate, Clinical benefit rate",0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
244.0,ALK,ALK_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Ceritinib,,Terminated,NCT02638909,,PCD,2018Mar29,Yes,Yes,Slow accrual,4.0,NCT02638909,,,"Disease control rate, Clinical benefit rate",0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
245.0,ALK,ALK_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Ceritinib,,Terminated,NCT02638909,,PCD,2018Mar29,Yes,Yes,Slow accrual,4.0,NCT02638909,,,"Disease control rate, Clinical benefit rate",0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
246.0,ALK,ALK_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Ceritinib,,Terminated,NCT02638909,,PCD,2018Mar29,Yes,Yes,Slow accrual,4.0,NCT02638909,,,"Disease control rate, Clinical benefit rate",0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
247.0,ALK,ALK_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Ceritinib,,Terminated,NCT02638909,,PCD,2018Mar29,Yes,Yes,Slow accrual,4.0,NCT02638909,,,"Disease control rate, Clinical benefit rate",0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
248.0,ALK,ALK_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Ceritinib,,Terminated,NCT02638909,,PCD,2018Mar29,Yes,Yes,Slow accrual,4.0,NCT02638909,,,"Disease control rate, Clinical benefit rate",0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
249.0,ALK,ALK_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Ceritinib,,Terminated,NCT02638909,,PCD,2018Mar29,Yes,Yes,Slow accrual,4.0,NCT02638909,,,"Disease control rate, Clinical benefit rate",0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
250.0,ALK,ALK_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Ceritinib,,Terminated,NCT02638909,,PCD,2018Mar29,Yes,Yes,Slow accrual,4.0,NCT02638909,,,"Disease control rate, Clinical benefit rate",0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
251.0,ALK,ALK_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Ceritinib,,Terminated,NCT02638909,,PCD,2018Mar29,Yes,Yes,Slow accrual,4.0,NCT02638909,,,"Disease control rate, Clinical benefit rate",0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
252.0,ALK,ALK_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Ceritinib,,Terminated,NCT02638909,,PCD,2018Mar29,Yes,Yes,Slow accrual,4.0,NCT02638909,,,"Disease control rate, Clinical benefit rate",0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
253.0,ALK,ALK_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Ceritinib,,Terminated,NCT02638909,,PCD,2018Mar29,Yes,Yes,Slow accrual,4.0,NCT02638909,,,"Disease control rate, Clinical benefit rate",0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
254.0,ALK,ALK_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Ceritinib,,Terminated,NCT02638909,,PCD,2018Mar29,Yes,Yes,Slow accrual,4.0,NCT02638909,,,"Disease control rate, Clinical benefit rate",0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
255.0,ALK,ALK_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Ceritinib,,Terminated,NCT02638909,,PCD,2018Mar29,Yes,Yes,Slow accrual,4.0,NCT02638909,,,"Disease control rate, Clinical benefit rate",0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
256.0,ALK,ALK_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Ceritinib,,Terminated,NCT02638909,,PCD,2018Mar29,Yes,Yes,Slow accrual,4.0,NCT02638909,,,"Disease control rate, Clinical benefit rate",0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
257.0,ALK,ALK_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Ceritinib,,Terminated,NCT02638909,,PCD,2018Mar29,Yes,Yes,Slow accrual,4.0,NCT02638909,,,"Disease control rate, Clinical benefit rate",0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
258.0,ALK,ALK_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Ceritinib,,Terminated,NCT02638909,,PCD,2018Mar29,Yes,Yes,Slow accrual,4.0,NCT02638909,,,"Disease control rate, Clinical benefit rate",0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
259.0,ALK,ALK_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Ceritinib,,Terminated,NCT02638909,,PCD,2018Mar29,Yes,Yes,Slow accrual,4.0,NCT02638909,,,"Disease control rate, Clinical benefit rate",0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
260.0,ALK,ALK_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Ceritinib,,Terminated,NCT02638909,,PCD,2018Mar29,Yes,Yes,Slow accrual,4.0,NCT02638909,,,"Disease control rate, Clinical benefit rate",0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
261.0,ALK,ALK_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Ceritinib,,Terminated,NCT02638909,,PCD,2018Mar29,Yes,Yes,Slow accrual,4.0,NCT02638909,,,"Disease control rate, Clinical benefit rate",0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
262.0,ALK,ALK_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Ceritinib,,Terminated,NCT02638909,,PCD,2018Mar29,Yes,Yes,Slow accrual,4.0,NCT02638909,,,"Disease control rate, Clinical benefit rate",0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
263.0,ALK,ALK_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Ceritinib,,Terminated,NCT02638909,,PCD,2018Mar29,Yes,Yes,Slow accrual,4.0,NCT02638909,,,"Disease control rate, Clinical benefit rate",0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
264.0,ALK,ALK_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Ceritinib,,Terminated,NCT02638909,,PCD,2018Mar29,Yes,Yes,Slow accrual,4.0,NCT02638909,,,"Disease control rate, Clinical benefit rate",0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
265.0,ALK,ALK_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Ceritinib,,Terminated,NCT02638909,,PCD,2018Mar29,Yes,Yes,Slow accrual,4.0,NCT02638909,,,"Disease control rate, Clinical benefit rate",0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
266.0,ALK,ALK_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Ceritinib,,Terminated,NCT02638909,,PCD,2018Mar29,Yes,Yes,Slow accrual,4.0,NCT02638909,,,"Disease control rate, Clinical benefit rate",0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
267.0,ALK,ALK_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Ceritinib,,Terminated,NCT02638909,,PCD,2018Mar29,Yes,Yes,Slow accrual,4.0,NCT02638909,,,"Disease control rate, Clinical benefit rate",0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
268.0,ALK,ALK_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Ceritinib,,Terminated,NCT02638909,,PCD,2018Mar29,Yes,Yes,Slow accrual,4.0,NCT02638909,,,"Disease control rate, Clinical benefit rate",0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
269.0,ALK,ALK_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Ceritinib,,Terminated,NCT02638909,,PCD,2018Mar29,Yes,Yes,Slow accrual,4.0,NCT02638909,,,"Disease control rate, Clinical benefit rate",0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
270.0,ALK,ALK_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Ceritinib,,Terminated,NCT02638909,,PCD,2018Mar29,Yes,Yes,Slow accrual,4.0,NCT02638909,,,"Disease control rate, Clinical benefit rate",0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
271.0,ALK,ALK_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Ceritinib,,Terminated,NCT02638909,,PCD,2018Mar29,Yes,Yes,Slow accrual,4.0,NCT02638909,,,"Disease control rate, Clinical benefit rate",0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
272.0,ALK,ALK_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Ceritinib,,Terminated,NCT02638909,,PCD,2018Mar29,Yes,Yes,Slow accrual,4.0,NCT02638909,,,"Disease control rate, Clinical benefit rate",0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
273.0,ALK,ALK_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Ceritinib,,Terminated,NCT02638909,,PCD,2018Mar29,Yes,Yes,Slow accrual,4.0,NCT02638909,,,"Disease control rate, Clinical benefit rate",0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
274.0,ALK,ALK_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Ceritinib,,Terminated,NCT02638909,,PCD,2018Mar29,Yes,Yes,Slow accrual,4.0,NCT02638909,,,"Disease control rate, Clinical benefit rate",0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
275.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
276.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
277.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
278.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
279.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
280.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
281.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
282.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
283.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
284.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
285.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
286.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
287.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
288.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
289.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
290.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
291.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
292.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
293.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
294.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
295.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
296.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
297.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
298.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
299.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
300.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
301.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
302.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
303.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
304.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
305.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
306.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
307.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
308.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
309.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
310.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
311.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
312.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
313.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
314.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
315.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
316.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
317.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
318.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
319.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
320.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
321.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
322.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
323.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
324.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
325.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
326.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
327.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
328.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
329.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
330.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
331.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
332.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
333.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
334.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
335.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
336.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
337.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
338.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
339.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
340.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
341.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
342.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
343.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
344.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
345.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
346.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
347.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
348.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
349.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
350.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
351.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
352.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
353.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
354.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
355.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
356.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
357.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
358.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
359.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
360.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
361.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
362.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
363.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
364.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
365.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
366.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
367.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
368.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
369.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
370.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
371.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
372.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
373.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
374.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
375.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
376.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
377.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
378.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
379.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
380.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
381.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
382.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
383.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
384.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
385.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
386.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
387.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
388.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
389.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
390.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
391.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
392.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
393.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
394.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
395.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
396.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
397.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
398.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
399.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
400.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
401.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
402.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
403.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
404.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
405.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
406.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
407.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
408.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
409.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
410.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
411.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
412.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
413.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
414.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
415.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
416.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
417.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
418.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
419.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
420.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
421.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
422.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
423.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
424.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
425.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
426.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
427.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
428.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
429.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
430.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
431.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
432.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
433.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
434.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
435.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
436.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
437.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
438.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
439.0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4015.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4016.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4017.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4018.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4019.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4020.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4021.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4022.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4023.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4024.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4025.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4026.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4027.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4028.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4029.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4030.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4031.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4032.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4033.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4034.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4035.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4036.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4037.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4038.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4039.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4040.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4041.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4042.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4043.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4044.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4045.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4046.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4047.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4048.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4049.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4050.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4051.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4052.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4053.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4054.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4055.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4056.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4057.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4058.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4059.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4060.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4061.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4062.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4063.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4064.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4065.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4066.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4067.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4068.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4069.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5060.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Approved FDA,Cetuximab,Required,Completed,NCT00079066,CO.17,PCD,2006Nov03,Expression confirmed,Yes,,4.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf,Previously-treated,,Overall survival,572.0,287.0,285.0,Best supportive care,,,,,,,,,,,,,,,,,,,,,,6.1,4.6,0.77,0.64-0.92,0.005,,,,,,,,,,,,,COSO28864826,2023Jan23,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5061.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Approved FDA,Cetuximab,Required,Completed,NCT00079066,CO.17,PCD,2006Nov03,Expression confirmed,Yes,,4.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf,Previously-treated,,Overall survival,572.0,287.0,285.0,Best supportive care,,,,,,,,,,,,,,,,,,,,,,6.1,4.6,0.77,0.64-0.92,0.005,,,,,,,,,,,,,COSO28864826,2023Jan23,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5062.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Approved FDA,Cetuximab,Required,Completed,NCT00079066,CO.17,PCD,2006Nov03,Expression confirmed,Yes,,4.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf,Previously-treated,,Overall survival,572.0,287.0,285.0,Best supportive care,,,,,,,,,,,,,,,,,,,,,,6.1,4.6,0.77,0.64-0.92,0.005,,,,,,,,,,,,,COSO28864826,2023Jan23,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5063.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Approved FDA,Cetuximab,Required,Completed,NCT00079066,CO.17,PCD,2006Nov03,Expression confirmed,Yes,,4.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf,Previously-treated,,Overall survival,572.0,287.0,285.0,Best supportive care,,,,,,,,,,,,,,,,,,,,,,6.1,4.6,0.77,0.64-0.92,0.005,,,,,,,,,,,,,COSO28864826,2023Jan23,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5064.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Approved FDA,Cetuximab,Required,Completed,NCT00079066,CO.17,PCD,2006Nov03,Expression confirmed,Yes,,4.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf,Previously-treated,,Overall survival,572.0,287.0,285.0,Best supportive care,,,,,,,,,,,,,,,,,,,,,,6.1,4.6,0.77,0.64-0.92,0.005,,,,,,,,,,,,,COSO28864826,2023Jan23,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5065.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Approved FDA,Cetuximab,Required,Completed,NCT00079066,CO.17,PCD,2006Nov03,Expression confirmed,Yes,,4.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf,Previously-treated,,Overall survival,572.0,287.0,285.0,Best supportive care,,,,,,,,,,,,,,,,,,,,,,6.1,4.6,0.77,0.64-0.92,0.005,,,,,,,,,,,,,COSO28864826,2023Jan23,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5066.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Approved FDA,Cetuximab,Required,Completed,NCT00079066,CO.17,PCD,2006Nov03,Expression confirmed,Yes,,4.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf,Previously-treated,,Overall survival,572.0,287.0,285.0,Best supportive care,,,,,,,,,,,,,,,,,,,,,,6.1,4.6,0.77,0.64-0.92,0.005,,,,,,,,,,,,,COSO28864826,2023Jan23,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5067.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Approved FDA,Cetuximab,Required,Completed,NCT00079066,CO.17,PCD,2006Nov03,Expression confirmed,Yes,,4.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf,Previously-treated,,Overall survival,572.0,287.0,285.0,Best supportive care,,,,,,,,,,,,,,,,,,,,,,6.1,4.6,0.77,0.64-0.92,0.005,,,,,,,,,,,,,COSO28864826,2023Jan23,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5068.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Approved FDA,Cetuximab,Required,Completed,NCT00079066,CO.17,PCD,2006Nov03,Expression confirmed,Yes,,4.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf,Previously-treated,,Overall survival,572.0,287.0,285.0,Best supportive care,,,,,,,,,,,,,,,,,,,,,,6.1,4.6,0.77,0.64-0.92,0.005,,,,,,,,,,,,,COSO28864826,2023Jan23,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5069.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Approved FDA,Cetuximab,Required,Completed,NCT00079066,CO.17,PCD,2006Nov03,Expression confirmed,Yes,,4.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf,Previously-treated,,Overall survival,572.0,287.0,285.0,Best supportive care,,,,,,,,,,,,,,,,,,,,,,6.1,4.6,0.77,0.64-0.92,0.005,,,,,,,,,,,,,COSO28864826,2023Jan23,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5070.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Approved FDA,Cetuximab,Required,Completed,NCT00079066,CO.17,PCD,2006Nov03,Expression confirmed,Yes,,4.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf,Previously-treated,,Overall survival,572.0,287.0,285.0,Best supportive care,,,,,,,,,,,,,,,,,,,,,,6.1,4.6,0.77,0.64-0.92,0.005,,,,,,,,,,,,,COSO28864826,2023Jan23,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5071.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Approved FDA,Cetuximab,Required,Completed,NCT00079066,CO.17,PCD,2006Nov03,Expression confirmed,Yes,,4.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf,Previously-treated,,Overall survival,572.0,287.0,285.0,Best supportive care,,,,,,,,,,,,,,,,,,,,,,6.1,4.6,0.77,0.64-0.92,0.005,,,,,,,,,,,,,COSO28864826,2023Jan23,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5072.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Approved FDA,Cetuximab,Required,Completed,NCT00079066,CO.17,PCD,2006Nov03,Expression confirmed,Yes,,4.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf,Previously-treated,,Overall survival,572.0,287.0,285.0,Best supportive care,,,,,,,,,,,,,,,,,,,,,,6.1,4.6,0.77,0.64-0.92,0.005,,,,,,,,,,,,,COSO28864826,2023Jan23,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5073.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Approved FDA,Cetuximab,Required,Completed,NCT00079066,CO.17,PCD,2006Nov03,Expression confirmed,Yes,,4.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf,Previously-treated,,Overall survival,572.0,287.0,285.0,Best supportive care,,,,,,,,,,,,,,,,,,,,,,6.1,4.6,0.77,0.64-0.92,0.005,,,,,,,,,,,,,COSO28864826,2023Jan23,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5074.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Approved FDA,Cetuximab,Required,Completed,NCT00079066,CO.17,PCD,2006Nov03,Expression confirmed,Yes,,4.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf,Previously-treated,,Overall survival,572.0,287.0,285.0,Best supportive care,,,,,,,,,,,,,,,,,,,,,,6.1,4.6,0.77,0.64-0.92,0.005,,,,,,,,,,,,,COSO28864826,2023Jan23,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5075.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Approved FDA,Cetuximab,Required,Completed,NCT00079066,CO.17,PCD,2006Nov03,Expression confirmed,Yes,,4.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf,Previously-treated,,Overall survival,572.0,287.0,285.0,Best supportive care,,,,,,,,,,,,,,,,,,,,,,6.1,4.6,0.77,0.64-0.92,0.005,,,,,,,,,,,,,COSO28864826,2023Jan23,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5076.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Approved FDA,Cetuximab,Required,Completed,NCT00079066,CO.17,PCD,2006Nov03,Expression confirmed,Yes,,4.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf,Previously-treated,,Overall survival,572.0,287.0,285.0,Best supportive care,,,,,,,,,,,,,,,,,,,,,,6.1,4.6,0.77,0.64-0.92,0.005,,,,,,,,,,,,,COSO28864826,2023Jan23,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5077.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Approved FDA,Cetuximab,Required,Completed,NCT00079066,CO.17,PCD,2006Nov03,Expression confirmed,Yes,,4.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf,Previously-treated,,Overall survival,572.0,287.0,285.0,Best supportive care,,,,,,,,,,,,,,,,,,,,,,6.1,4.6,0.77,0.64-0.92,0.005,,,,,,,,,,,,,COSO28864826,2023Jan23,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5078.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Approved FDA,Cetuximab,Required,Completed,NCT00079066,CO.17,PCD,2006Nov03,Expression confirmed,Yes,,4.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf,Previously-treated,,Overall survival,572.0,287.0,285.0,Best supportive care,,,,,,,,,,,,,,,,,,,,,,6.1,4.6,0.77,0.64-0.92,0.005,,,,,,,,,,,,,COSO28864826,2023Jan23,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5079.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Approved FDA,Cetuximab,Required,Completed,NCT00079066,CO.17,PCD,2006Nov03,Expression confirmed,Yes,,4.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf,Previously-treated,,Overall survival,572.0,287.0,285.0,Best supportive care,,,,,,,,,,,,,,,,,,,,,,6.1,4.6,0.77,0.64-0.92,0.005,,,,,,,,,,,,,COSO28864826,2023Jan23,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5080.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Approved FDA,Cetuximab,Required,Completed,NCT00079066,CO.17,PCD,2006Nov03,Expression confirmed,Yes,,4.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf,Previously-treated,,Overall survival,572.0,287.0,285.0,Best supportive care,,,,,,,,,,,,,,,,,,,,,,6.1,4.6,0.77,0.64-0.92,0.005,,,,,,,,,,,,,COSO28864826,2023Jan23,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5081.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Approved FDA,Cetuximab,Required,Completed,NCT00079066,CO.17,PCD,2006Nov03,Expression confirmed,Yes,,4.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf,Previously-treated,,Overall survival,572.0,287.0,285.0,Best supportive care,,,,,,,,,,,,,,,,,,,,,,6.1,4.6,0.77,0.64-0.92,0.005,,,,,,,,,,,,,COSO28864826,2023Jan23,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5082.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Approved FDA,Cetuximab,Required,Completed,NCT00079066,CO.17,PCD,2006Nov03,Expression confirmed,Yes,,4.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf,Previously-treated,,Overall survival,572.0,287.0,285.0,Best supportive care,,,,,,,,,,,,,,,,,,,,,,6.1,4.6,0.77,0.64-0.92,0.005,,,,,,,,,,,,,COSO28864826,2023Jan23,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5083.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Approved FDA,Cetuximab,Required,Completed,NCT00079066,CO.17,PCD,2006Nov03,Expression confirmed,Yes,,4.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf,Previously-treated,,Overall survival,572.0,287.0,285.0,Best supportive care,,,,,,,,,,,,,,,,,,,,,,6.1,4.6,0.77,0.64-0.92,0.005,,,,,,,,,,,,,COSO28864826,2023Jan23,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5084.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Approved FDA,Cetuximab,Required,Completed,NCT00079066,CO.17,PCD,2006Nov03,Expression confirmed,Yes,,4.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf,Previously-treated,,Overall survival,572.0,287.0,285.0,Best supportive care,,,,,,,,,,,,,,,,,,,,,,6.1,4.6,0.77,0.64-0.92,0.005,,,,,,,,,,,,,COSO28864826,2023Jan23,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5085.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Approved FDA,Cetuximab,Required,Completed,NCT00079066,CO.17,PCD,2006Nov03,Expression confirmed,Yes,,4.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf,Previously-treated,,Overall survival,572.0,287.0,285.0,Best supportive care,,,,,,,,,,,,,,,,,,,,,,6.1,4.6,0.77,0.64-0.92,0.005,,,,,,,,,,,,,COSO28864826,2023Jan23,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5086.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Approved FDA,Cetuximab,Required,Completed,NCT00079066,CO.17,PCD,2006Nov03,Expression confirmed,Yes,,4.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf,Previously-treated,,Overall survival,572.0,287.0,285.0,Best supportive care,,,,,,,,,,,,,,,,,,,,,,6.1,4.6,0.77,0.64-0.92,0.005,,,,,,,,,,,,,COSO28864826,2023Jan23,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5087.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Approved FDA,Cetuximab,Required,Completed,NCT00079066,CO.17,PCD,2006Nov03,Expression confirmed,Yes,,4.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf,Previously-treated,,Overall survival,572.0,287.0,285.0,Best supportive care,,,,,,,,,,,,,,,,,,,,,,6.1,4.6,0.77,0.64-0.92,0.005,,,,,,,,,,,,,COSO28864826,2023Jan23,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5088.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Approved FDA,Cetuximab,Required,Completed,NCT00079066,CO.17,PCD,2006Nov03,Expression confirmed,Yes,,4.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf,Previously-treated,,Overall survival,572.0,287.0,285.0,Best supportive care,,,,,,,,,,,,,,,,,,,,,,6.1,4.6,0.77,0.64-0.92,0.005,,,,,,,,,,,,,COSO28864826,2023Jan23,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5089.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Approved FDA,Cetuximab,Required,Completed,NCT00079066,CO.17,PCD,2006Nov03,Expression confirmed,Yes,,4.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf,Previously-treated,,Overall survival,572.0,287.0,285.0,Best supportive care,,,,,,,,,,,,,,,,,,,,,,6.1,4.6,0.77,0.64-0.92,0.005,,,,,,,,,,,,,COSO28864826,2023Jan23,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5090.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Approved FDA,Cetuximab,Required,Completed,NCT00079066,CO.17,PCD,2006Nov03,Expression confirmed,Yes,,4.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf,Previously-treated,,Overall survival,572.0,287.0,285.0,Best supportive care,,,,,,,,,,,,,,,,,,,,,,6.1,4.6,0.77,0.64-0.92,0.005,,,,,,,,,,,,,COSO28864826,2023Jan23,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5091.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Approved FDA,Cetuximab,Required,Completed,NCT00079066,CO.17,PCD,2006Nov03,Expression confirmed,Yes,,4.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf,Previously-treated,,Overall survival,572.0,287.0,285.0,Best supportive care,,,,,,,,,,,,,,,,,,,,,,6.1,4.6,0.77,0.64-0.92,0.005,,,,,,,,,,,,,COSO28864826,2023Jan23,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5092.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Approved FDA,Cetuximab,Required,Completed,NCT00079066,CO.17,PCD,2006Nov03,Expression confirmed,Yes,,4.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf,Previously-treated,,Overall survival,572.0,287.0,285.0,Best supportive care,,,,,,,,,,,,,,,,,,,,,,6.1,4.6,0.77,0.64-0.92,0.005,,,,,,,,,,,,,COSO28864826,2023Jan23,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5093.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Approved FDA,Cetuximab,Required,Completed,NCT00079066,CO.17,PCD,2006Nov03,Expression confirmed,Yes,,4.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf,Previously-treated,,Overall survival,572.0,287.0,285.0,Best supportive care,,,,,,,,,,,,,,,,,,,,,,6.1,4.6,0.77,0.64-0.92,0.005,,,,,,,,,,,,,COSO28864826,2023Jan23,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5094.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Approved FDA,Cetuximab,Required,Completed,NCT00079066,CO.17,PCD,2006Nov03,Expression confirmed,Yes,,4.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf,Previously-treated,,Overall survival,572.0,287.0,285.0,Best supportive care,,,,,,,,,,,,,,,,,,,,,,6.1,4.6,0.77,0.64-0.92,0.005,,,,,,,,,,,,,COSO28864826,2023Jan23,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5095.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Approved FDA,Cetuximab,Required,Completed,NCT00079066,CO.17,PCD,2006Nov03,Expression confirmed,Yes,,4.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf,Previously-treated,,Overall survival,572.0,287.0,285.0,Best supportive care,,,,,,,,,,,,,,,,,,,,,,6.1,4.6,0.77,0.64-0.92,0.005,,,,,,,,,,,,,COSO28864826,2023Jan23,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5096.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Approved FDA,Cetuximab,Required,Completed,NCT00079066,CO.17,PCD,2006Nov03,Expression confirmed,Yes,,4.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf,Previously-treated,,Overall survival,572.0,287.0,285.0,Best supportive care,,,,,,,,,,,,,,,,,,,,,,6.1,4.6,0.77,0.64-0.92,0.005,,,,,,,,,,,,,COSO28864826,2023Jan23,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5097.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Approved FDA,Cetuximab,Required,Completed,NCT00079066,CO.17,PCD,2006Nov03,Expression confirmed,Yes,,4.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf,Previously-treated,,Overall survival,572.0,287.0,285.0,Best supportive care,,,,,,,,,,,,,,,,,,,,,,6.1,4.6,0.77,0.64-0.92,0.005,,,,,,,,,,,,,COSO28864826,2023Jan23,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5098.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Approved FDA,Cetuximab,Required,Completed,NCT00079066,CO.17,PCD,2006Nov03,Expression confirmed,Yes,,4.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf,Previously-treated,,Overall survival,572.0,287.0,285.0,Best supportive care,,,,,,,,,,,,,,,,,,,,,,6.1,4.6,0.77,0.64-0.92,0.005,,,,,,,,,,,,,COSO28864826,2023Jan23,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5099.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Approved FDA,Cetuximab,Required,Completed,NCT00079066,CO.17,PCD,2006Nov03,Expression confirmed,Yes,,4.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf,Previously-treated,,Overall survival,572.0,287.0,285.0,Best supportive care,,,,,,,,,,,,,,,,,,,,,,6.1,4.6,0.77,0.64-0.92,0.005,,,,,,,,,,,,,COSO28864826,2023Jan23,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5100.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Approved FDA,Cetuximab,Required,Completed,NCT00079066,CO.17,PCD,2006Nov03,Expression confirmed,Yes,,4.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf,Previously-treated,,Overall survival,572.0,287.0,285.0,Best supportive care,,,,,,,,,,,,,,,,,,,,,,6.1,4.6,0.77,0.64-0.92,0.005,,,,,,,,,,,,,COSO28864826,2023Jan23,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5101.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Approved FDA,Cetuximab,Required,Completed,NCT00079066,CO.17,PCD,2006Nov03,Expression confirmed,Yes,,4.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf,Previously-treated,,Overall survival,572.0,287.0,285.0,Best supportive care,,,,,,,,,,,,,,,,,,,,,,6.1,4.6,0.77,0.64-0.92,0.005,,,,,,,,,,,,,COSO28864826,2023Jan23,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5102.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Approved FDA,Cetuximab,Required,Completed,NCT00079066,CO.17,PCD,2006Nov03,Expression confirmed,Yes,,4.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf,Previously-treated,,Overall survival,572.0,287.0,285.0,Best supportive care,,,,,,,,,,,,,,,,,,,,,,6.1,4.6,0.77,0.64-0.92,0.005,,,,,,,,,,,,,COSO28864826,2023Jan23,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5103.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Approved FDA,Cetuximab,Required,Completed,NCT00079066,CO.17,PCD,2006Nov03,Expression confirmed,Yes,,4.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf,Previously-treated,,Overall survival,572.0,287.0,285.0,Best supportive care,,,,,,,,,,,,,,,,,,,,,,6.1,4.6,0.77,0.64-0.92,0.005,,,,,,,,,,,,,COSO28864826,2023Jan23,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5104.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Approved FDA,Cetuximab,Required,Completed,NCT00079066,CO.17,PCD,2006Nov03,Expression confirmed,Yes,,4.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf,Previously-treated,,Overall survival,572.0,287.0,285.0,Best supportive care,,,,,,,,,,,,,,,,,,,,,,6.1,4.6,0.77,0.64-0.92,0.005,,,,,,,,,,,,,COSO28864826,2023Jan23,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5105.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Approved FDA,Cetuximab,Required,Completed,NCT00079066,CO.17,PCD,2006Nov03,Expression confirmed,Yes,,4.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf,Previously-treated,,Overall survival,572.0,287.0,285.0,Best supportive care,,,,,,,,,,,,,,,,,,,,,,6.1,4.6,0.77,0.64-0.92,0.005,,,,,,,,,,,,,COSO28864826,2023Jan23,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5106.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Approved FDA,Cetuximab,Required,Completed,NCT00079066,CO.17,PCD,2006Nov03,Expression confirmed,Yes,,4.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf,Previously-treated,,Overall survival,572.0,287.0,285.0,Best supportive care,,,,,,,,,,,,,,,,,,,,,,6.1,4.6,0.77,0.64-0.92,0.005,,,,,,,,,,,,,COSO28864826,2023Jan23,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5107.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Approved FDA,Cetuximab,Required,Completed,NCT00079066,CO.17,PCD,2006Nov03,Expression confirmed,Yes,,4.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf,Previously-treated,,Overall survival,572.0,287.0,285.0,Best supportive care,,,,,,,,,,,,,,,,,,,,,,6.1,4.6,0.77,0.64-0.92,0.005,,,,,,,,,,,,,COSO28864826,2023Jan23,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5108.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Approved FDA,Cetuximab,Required,Completed,NCT00079066,CO.17,PCD,2006Nov03,Expression confirmed,Yes,,4.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf,Previously-treated,,Overall survival,572.0,287.0,285.0,Best supportive care,,,,,,,,,,,,,,,,,,,,,,6.1,4.6,0.77,0.64-0.92,0.005,,,,,,,,,,,,,COSO28864826,2023Jan23,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5109.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Approved FDA,Cetuximab,Required,Completed,NCT00079066,CO.17,PCD,2006Nov03,Expression confirmed,Yes,,4.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf,Previously-treated,,Overall survival,572.0,287.0,285.0,Best supportive care,,,,,,,,,,,,,,,,,,,,,,6.1,4.6,0.77,0.64-0.92,0.005,,,,,,,,,,,,,COSO28864826,2023Jan23,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5110.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Approved FDA,Cetuximab,Required,Completed,NCT00079066,CO.17,PCD,2006Nov03,Expression confirmed,Yes,,4.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf,Previously-treated,,Overall survival,572.0,287.0,285.0,Best supportive care,,,,,,,,,,,,,,,,,,,,,,6.1,4.6,0.77,0.64-0.92,0.005,,,,,,,,,,,,,COSO28864826,2023Jan23,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5111.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Approved FDA,Cetuximab,Required,Completed,NCT00079066,CO.17,PCD,2006Nov03,Expression confirmed,Yes,,4.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf,Previously-treated,,Overall survival,572.0,287.0,285.0,Best supportive care,,,,,,,,,,,,,,,,,,,,,,6.1,4.6,0.77,0.64-0.92,0.005,,,,,,,,,,,,,COSO28864826,2023Jan23,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5112.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Approved FDA,Cetuximab,Required,Completed,NCT00079066,CO.17,PCD,2006Nov03,Expression confirmed,Yes,,4.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf,Previously-treated,,Overall survival,572.0,287.0,285.0,Best supportive care,,,,,,,,,,,,,,,,,,,,,,6.1,4.6,0.77,0.64-0.92,0.005,,,,,,,,,,,,,COSO28864826,2023Jan23,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5113.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Approved FDA,Cetuximab,Required,Completed,NCT00079066,CO.17,PCD,2006Nov03,Expression confirmed,Yes,,4.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf,Previously-treated,,Overall survival,572.0,287.0,285.0,Best supportive care,,,,,,,,,,,,,,,,,,,,,,6.1,4.6,0.77,0.64-0.92,0.005,,,,,,,,,,,,,COSO28864826,2023Jan23,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5114.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Approved FDA,Cetuximab,Required,Completed,NCT00079066,CO.17,PCD,2006Nov03,Expression confirmed,Yes,,4.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf,Previously-treated,,Overall survival,572.0,287.0,285.0,Best supportive care,,,,,,,,,,,,,,,,,,,,,,6.1,4.6,0.77,0.64-0.92,0.005,,,,,,,,,,,,,COSO28864826,2023Jan23,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
9405.0,KRAS,KRAS_G12 or KRAS_G13,55500243 + 55559231 + 55756103,,p.G12X + p.G13=,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Completed,NCT00079066,CO.17,PCD,2006Nov03,Yes,Yes,No benefit of treatment,1.0,18946061,,,Overall survival,151.0,75.0,76.0,FOLFIRI + Imgatuzumab,,,,,,,,,1.8,1.8,,,,,,,,,,,,4.5,4.6,0.98,0.7-1.37,0.89,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
9406.0,KRAS,KRAS_G12 or KRAS_G13,55500243 + 55559231 + 55756103,,p.G12X + p.G13=,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Completed,NCT00079066,CO.17,PCD,2006Nov03,Yes,Yes,No benefit of treatment,1.0,18946061,,,Overall survival,151.0,75.0,76.0,FOLFIRI + Imgatuzumab,,,,,,,,,1.8,1.8,,,,,,,,,,,,4.5,4.6,0.98,0.7-1.37,0.89,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
9407.0,KRAS,KRAS_G12 or KRAS_G13,55500243 + 55559231 + 55756103,,p.G12X + p.G13=,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Completed,NCT00079066,CO.17,PCD,2006Nov03,Yes,Yes,No benefit of treatment,1.0,18946061,,,Overall survival,151.0,75.0,76.0,FOLFIRI + Imgatuzumab,,,,,,,,,1.8,1.8,,,,,,,,,,,,4.5,4.6,0.98,0.7-1.37,0.89,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
9408.0,KRAS,KRAS_G12 or KRAS_G13,55500243 + 55559231 + 55756103,,p.G12X + p.G13=,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Completed,NCT00079066,CO.17,PCD,2006Nov03,Yes,Yes,No benefit of treatment,1.0,18946061,,,Overall survival,151.0,75.0,76.0,FOLFIRI + Imgatuzumab,,,,,,,,,1.8,1.8,,,,,,,,,,,,4.5,4.6,0.98,0.7-1.37,0.89,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
9409.0,KRAS,KRAS_G12 or KRAS_G13,55500243 + 55559231 + 55756103,,p.G12X + p.G13=,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Completed,NCT00079066,CO.17,PCD,2006Nov03,Yes,Yes,No benefit of treatment,1.0,18946061,,,Overall survival,151.0,75.0,76.0,FOLFIRI + Imgatuzumab,,,,,,,,,1.8,1.8,,,,,,,,,,,,4.5,4.6,0.98,0.7-1.37,0.89,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
9410.0,KRAS,KRAS_G12 or KRAS_G13,55500243 + 55559231 + 55756103,,p.G12X + p.G13=,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Completed,NCT00079066,CO.17,PCD,2006Nov03,Yes,Yes,No benefit of treatment,1.0,18946061,,,Overall survival,151.0,75.0,76.0,FOLFIRI + Imgatuzumab,,,,,,,,,1.8,1.8,,,,,,,,,,,,4.5,4.6,0.98,0.7-1.37,0.89,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
9411.0,KRAS,KRAS_G12 or KRAS_G13,55500243 + 55559231 + 55756103,,p.G12X + p.G13=,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Completed,NCT00079066,CO.17,PCD,2006Nov03,Yes,Yes,No benefit of treatment,1.0,18946061,,,Overall survival,151.0,75.0,76.0,FOLFIRI + Imgatuzumab,,,,,,,,,1.8,1.8,,,,,,,,,,,,4.5,4.6,0.98,0.7-1.37,0.89,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
9412.0,KRAS,KRAS_G12 or KRAS_G13,55500243 + 55559231 + 55756103,,p.G12X + p.G13=,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Completed,NCT00079066,CO.17,PCD,2006Nov03,Yes,Yes,No benefit of treatment,1.0,18946061,,,Overall survival,151.0,75.0,76.0,FOLFIRI + Imgatuzumab,,,,,,,,,1.8,1.8,,,,,,,,,,,,4.5,4.6,0.98,0.7-1.37,0.89,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
9413.0,KRAS,KRAS_G12 or KRAS_G13,55500243 + 55559231 + 55756103,,p.G12X + p.G13=,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Completed,NCT00079066,CO.17,PCD,2006Nov03,Yes,Yes,No benefit of treatment,1.0,18946061,,,Overall survival,151.0,75.0,76.0,FOLFIRI + Imgatuzumab,,,,,,,,,1.8,1.8,,,,,,,,,,,,4.5,4.6,0.98,0.7-1.37,0.89,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
9414.0,KRAS,KRAS_G12 or KRAS_G13,55500243 + 55559231 + 55756103,,p.G12X + p.G13=,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Completed,NCT00079066,CO.17,PCD,2006Nov03,Yes,Yes,No benefit of treatment,1.0,18946061,,,Overall survival,151.0,75.0,76.0,FOLFIRI + Imgatuzumab,,,,,,,,,1.8,1.8,,,,,,,,,,,,4.5,4.6,0.98,0.7-1.37,0.89,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
9415.0,KRAS,KRAS_G12 or KRAS_G13,55500243 + 55559231 + 55756103,,p.G12X + p.G13=,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Completed,NCT00079066,CO.17,PCD,2006Nov03,Yes,Yes,No benefit of treatment,1.0,18946061,,,Overall survival,151.0,75.0,76.0,FOLFIRI + Imgatuzumab,,,,,,,,,1.8,1.8,,,,,,,,,,,,4.5,4.6,0.98,0.7-1.37,0.89,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
9416.0,KRAS,KRAS_G12 or KRAS_G13,55500243 + 55559231 + 55756103,,p.G12X + p.G13=,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Completed,NCT00079066,CO.17,PCD,2006Nov03,Yes,Yes,No benefit of treatment,1.0,18946061,,,Overall survival,151.0,75.0,76.0,FOLFIRI + Imgatuzumab,,,,,,,,,1.8,1.8,,,,,,,,,,,,4.5,4.6,0.98,0.7-1.37,0.89,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
9417.0,KRAS,KRAS_G12 or KRAS_G13,55500243 + 55559231 + 55756103,,p.G12X + p.G13=,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Completed,NCT00079066,CO.17,PCD,2006Nov03,Yes,Yes,No benefit of treatment,1.0,18946061,,,Overall survival,151.0,75.0,76.0,FOLFIRI + Imgatuzumab,,,,,,,,,1.8,1.8,,,,,,,,,,,,4.5,4.6,0.98,0.7-1.37,0.89,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
9418.0,KRAS,KRAS_G12 or KRAS_G13,55500243 + 55559231 + 55756103,,p.G12X + p.G13=,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Completed,NCT00079066,CO.17,PCD,2006Nov03,Yes,Yes,No benefit of treatment,1.0,18946061,,,Overall survival,151.0,75.0,76.0,FOLFIRI + Imgatuzumab,,,,,,,,,1.8,1.8,,,,,,,,,,,,4.5,4.6,0.98,0.7-1.37,0.89,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
9419.0,KRAS,KRAS_G12 or KRAS_G13,55500243 + 55559231 + 55756103,,p.G12X + p.G13=,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Completed,NCT00079066,CO.17,PCD,2006Nov03,Yes,Yes,No benefit of treatment,1.0,18946061,,,Overall survival,151.0,75.0,76.0,FOLFIRI + Imgatuzumab,,,,,,,,,1.8,1.8,,,,,,,,,,,,4.5,4.6,0.98,0.7-1.37,0.89,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
9420.0,KRAS,KRAS_G12 or KRAS_G13,55500243 + 55559231 + 55756103,,p.G12X + p.G13=,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Completed,NCT00079066,CO.17,PCD,2006Nov03,Yes,Yes,No benefit of treatment,1.0,18946061,,,Overall survival,151.0,75.0,76.0,FOLFIRI + Imgatuzumab,,,,,,,,,1.8,1.8,,,,,,,,,,,,4.5,4.6,0.98,0.7-1.37,0.89,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
9421.0,KRAS,KRAS_G12 or KRAS_G13,55500243 + 55559231 + 55756103,,p.G12X + p.G13=,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Completed,NCT00079066,CO.17,PCD,2006Nov03,Yes,Yes,No benefit of treatment,1.0,18946061,,,Overall survival,151.0,75.0,76.0,FOLFIRI + Imgatuzumab,,,,,,,,,1.8,1.8,,,,,,,,,,,,4.5,4.6,0.98,0.7-1.37,0.89,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
9422.0,KRAS,KRAS_G12 or KRAS_G13,55500243 + 55559231 + 55756103,,p.G12X + p.G13=,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Completed,NCT00079066,CO.17,PCD,2006Nov03,Yes,Yes,No benefit of treatment,1.0,18946061,,,Overall survival,151.0,75.0,76.0,FOLFIRI + Imgatuzumab,,,,,,,,,1.8,1.8,,,,,,,,,,,,4.5,4.6,0.98,0.7-1.37,0.89,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
9423.0,KRAS,KRAS_G12 or KRAS_G13,55500243 + 55559231 + 55756103,,p.G12X + p.G13=,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Completed,NCT00079066,CO.17,PCD,2006Nov03,Yes,Yes,No benefit of treatment,1.0,18946061,,,Overall survival,151.0,75.0,76.0,FOLFIRI + Imgatuzumab,,,,,,,,,1.8,1.8,,,,,,,,,,,,4.5,4.6,0.98,0.7-1.37,0.89,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
9424.0,KRAS,KRAS_G12 or KRAS_G13,55500243 + 55559231 + 55756103,,p.G12X + p.G13=,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Completed,NCT00079066,CO.17,PCD,2006Nov03,Yes,Yes,No benefit of treatment,1.0,18946061,,,Overall survival,151.0,75.0,76.0,FOLFIRI + Imgatuzumab,,,,,,,,,1.8,1.8,,,,,,,,,,,,4.5,4.6,0.98,0.7-1.37,0.89,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
9425.0,KRAS,KRAS_G12 or KRAS_G13,55500243 + 55559231 + 55756103,,p.G12X + p.G13=,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Completed,NCT00079066,CO.17,PCD,2006Nov03,Yes,Yes,No benefit of treatment,1.0,18946061,,,Overall survival,151.0,75.0,76.0,FOLFIRI + Imgatuzumab,,,,,,,,,1.8,1.8,,,,,,,,,,,,4.5,4.6,0.98,0.7-1.37,0.89,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
9426.0,KRAS,KRAS_G12 or KRAS_G13,55500243 + 55559231 + 55756103,,p.G12X + p.G13=,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Completed,NCT00079066,CO.17,PCD,2006Nov03,Yes,Yes,No benefit of treatment,1.0,18946061,,,Overall survival,151.0,75.0,76.0,FOLFIRI + Imgatuzumab,,,,,,,,,1.8,1.8,,,,,,,,,,,,4.5,4.6,0.98,0.7-1.37,0.89,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
9427.0,KRAS,KRAS_G12 or KRAS_G13,55500243 + 55559231 + 55756103,,p.G12X + p.G13=,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Completed,NCT00079066,CO.17,PCD,2006Nov03,Yes,Yes,No benefit of treatment,1.0,18946061,,,Overall survival,151.0,75.0,76.0,FOLFIRI + Imgatuzumab,,,,,,,,,1.8,1.8,,,,,,,,,,,,4.5,4.6,0.98,0.7-1.37,0.89,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
9428.0,KRAS,KRAS_G12 or KRAS_G13,55500243 + 55559231 + 55756103,,p.G12X + p.G13=,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Completed,NCT00079066,CO.17,PCD,2006Nov03,Yes,Yes,No benefit of treatment,1.0,18946061,,,Overall survival,151.0,75.0,76.0,FOLFIRI + Imgatuzumab,,,,,,,,,1.8,1.8,,,,,,,,,,,,4.5,4.6,0.98,0.7-1.37,0.89,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
9429.0,KRAS,KRAS_G12 or KRAS_G13,55500243 + 55559231 + 55756103,,p.G12X + p.G13=,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Completed,NCT00079066,CO.17,PCD,2006Nov03,Yes,Yes,No benefit of treatment,1.0,18946061,,,Overall survival,151.0,75.0,76.0,FOLFIRI + Imgatuzumab,,,,,,,,,1.8,1.8,,,,,,,,,,,,4.5,4.6,0.98,0.7-1.37,0.89,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
9430.0,KRAS,KRAS_G12 or KRAS_G13,55500243 + 55559231 + 55756103,,p.G12X + p.G13=,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Completed,NCT00079066,CO.17,PCD,2006Nov03,Yes,Yes,No benefit of treatment,1.0,18946061,,,Overall survival,151.0,75.0,76.0,FOLFIRI + Imgatuzumab,,,,,,,,,1.8,1.8,,,,,,,,,,,,4.5,4.6,0.98,0.7-1.37,0.89,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
9431.0,KRAS,KRAS_G12 or KRAS_G13,55500243 + 55559231 + 55756103,,p.G12X + p.G13=,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Completed,NCT00079066,CO.17,PCD,2006Nov03,Yes,Yes,No benefit of treatment,1.0,18946061,,,Overall survival,151.0,75.0,76.0,FOLFIRI + Imgatuzumab,,,,,,,,,1.8,1.8,,,,,,,,,,,,4.5,4.6,0.98,0.7-1.37,0.89,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
9432.0,KRAS,KRAS_G12 or KRAS_G13,55500243 + 55559231 + 55756103,,p.G12X + p.G13=,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Completed,NCT00079066,CO.17,PCD,2006Nov03,Yes,Yes,No benefit of treatment,1.0,18946061,,,Overall survival,151.0,75.0,76.0,FOLFIRI + Imgatuzumab,,,,,,,,,1.8,1.8,,,,,,,,,,,,4.5,4.6,0.98,0.7-1.37,0.89,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
9433.0,KRAS,KRAS_G12 or KRAS_G13,55500243 + 55559231 + 55756103,,p.G12X + p.G13=,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Completed,NCT00079066,CO.17,PCD,2006Nov03,Yes,Yes,No benefit of treatment,1.0,18946061,,,Overall survival,151.0,75.0,76.0,FOLFIRI + Imgatuzumab,,,,,,,,,1.8,1.8,,,,,,,,,,,,4.5,4.6,0.98,0.7-1.37,0.89,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
9434.0,KRAS,KRAS_G12 or KRAS_G13,55500243 + 55559231 + 55756103,,p.G12X + p.G13=,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Completed,NCT00079066,CO.17,PCD,2006Nov03,Yes,Yes,No benefit of treatment,1.0,18946061,,,Overall survival,151.0,75.0,76.0,FOLFIRI + Imgatuzumab,,,,,,,,,1.8,1.8,,,,,,,,,,,,4.5,4.6,0.98,0.7-1.37,0.89,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
9435.0,KRAS,KRAS_G12 or KRAS_G13,55500243 + 55559231 + 55756103,,p.G12X + p.G13=,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Completed,NCT00079066,CO.17,PCD,2006Nov03,Yes,Yes,No benefit of treatment,1.0,18946061,,,Overall survival,151.0,75.0,76.0,FOLFIRI + Imgatuzumab,,,,,,,,,1.8,1.8,,,,,,,,,,,,4.5,4.6,0.98,0.7-1.37,0.89,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
9436.0,KRAS,KRAS_G12 or KRAS_G13,55500243 + 55559231 + 55756103,,p.G12X + p.G13=,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Completed,NCT00079066,CO.17,PCD,2006Nov03,Yes,Yes,No benefit of treatment,1.0,18946061,,,Overall survival,151.0,75.0,76.0,FOLFIRI + Imgatuzumab,,,,,,,,,1.8,1.8,,,,,,,,,,,,4.5,4.6,0.98,0.7-1.37,0.89,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
9437.0,KRAS,KRAS_G12 or KRAS_G13,55500243 + 55559231 + 55756103,,p.G12X + p.G13=,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Completed,NCT00079066,CO.17,PCD,2006Nov03,Yes,Yes,No benefit of treatment,1.0,18946061,,,Overall survival,151.0,75.0,76.0,FOLFIRI + Imgatuzumab,,,,,,,,,1.8,1.8,,,,,,,,,,,,4.5,4.6,0.98,0.7-1.37,0.89,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
9438.0,KRAS,KRAS_G12 or KRAS_G13,55500243 + 55559231 + 55756103,,p.G12X + p.G13=,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Completed,NCT00079066,CO.17,PCD,2006Nov03,Yes,Yes,No benefit of treatment,1.0,18946061,,,Overall survival,151.0,75.0,76.0,FOLFIRI + Imgatuzumab,,,,,,,,,1.8,1.8,,,,,,,,,,,,4.5,4.6,0.98,0.7-1.37,0.89,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
9439.0,KRAS,KRAS_G12 or KRAS_G13,55500243 + 55559231 + 55756103,,p.G12X + p.G13=,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Completed,NCT00079066,CO.17,PCD,2006Nov03,Yes,Yes,No benefit of treatment,1.0,18946061,,,Overall survival,151.0,75.0,76.0,FOLFIRI + Imgatuzumab,,,,,,,,,1.8,1.8,,,,,,,,,,,,4.5,4.6,0.98,0.7-1.37,0.89,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
9440.0,KRAS,KRAS_G12 or KRAS_G13,55500243 + 55559231 + 55756103,,p.G12X + p.G13=,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Completed,NCT00079066,CO.17,PCD,2006Nov03,Yes,Yes,No benefit of treatment,1.0,18946061,,,Overall survival,151.0,75.0,76.0,FOLFIRI + Imgatuzumab,,,,,,,,,1.8,1.8,,,,,,,,,,,,4.5,4.6,0.98,0.7-1.37,0.89,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
9441.0,KRAS,KRAS_G12 or KRAS_G13,55500243 + 55559231 + 55756103,,p.G12X + p.G13=,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Completed,NCT00079066,CO.17,PCD,2006Nov03,Yes,Yes,No benefit of treatment,1.0,18946061,,,Overall survival,151.0,75.0,76.0,FOLFIRI + Imgatuzumab,,,,,,,,,1.8,1.8,,,,,,,,,,,,4.5,4.6,0.98,0.7-1.37,0.89,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
9442.0,KRAS,KRAS_G12 or KRAS_G13,55500243 + 55559231 + 55756103,,p.G12X + p.G13=,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Completed,NCT00079066,CO.17,PCD,2006Nov03,Yes,Yes,No benefit of treatment,1.0,18946061,,,Overall survival,151.0,75.0,76.0,FOLFIRI + Imgatuzumab,,,,,,,,,1.8,1.8,,,,,,,,,,,,4.5,4.6,0.98,0.7-1.37,0.89,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
9443.0,KRAS,KRAS_G12 or KRAS_G13,55500243 + 55559231 + 55756103,,p.G12X + p.G13=,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Completed,NCT00079066,CO.17,PCD,2006Nov03,Yes,Yes,No benefit of treatment,1.0,18946061,,,Overall survival,151.0,75.0,76.0,FOLFIRI + Imgatuzumab,,,,,,,,,1.8,1.8,,,,,,,,,,,,4.5,4.6,0.98,0.7-1.37,0.89,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
9444.0,KRAS,KRAS_G12 or KRAS_G13,55500243 + 55559231 + 55756103,,p.G12X + p.G13=,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Completed,NCT00079066,CO.17,PCD,2006Nov03,Yes,Yes,No benefit of treatment,1.0,18946061,,,Overall survival,151.0,75.0,76.0,FOLFIRI + Imgatuzumab,,,,,,,,,1.8,1.8,,,,,,,,,,,,4.5,4.6,0.98,0.7-1.37,0.89,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
9445.0,KRAS,KRAS_G12 or KRAS_G13,55500243 + 55559231 + 55756103,,p.G12X + p.G13=,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Completed,NCT00079066,CO.17,PCD,2006Nov03,Yes,Yes,No benefit of treatment,1.0,18946061,,,Overall survival,151.0,75.0,76.0,FOLFIRI + Imgatuzumab,,,,,,,,,1.8,1.8,,,,,,,,,,,,4.5,4.6,0.98,0.7-1.37,0.89,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
9446.0,KRAS,KRAS_G12 or KRAS_G13,55500243 + 55559231 + 55756103,,p.G12X + p.G13=,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Completed,NCT00079066,CO.17,PCD,2006Nov03,Yes,Yes,No benefit of treatment,1.0,18946061,,,Overall survival,151.0,75.0,76.0,FOLFIRI + Imgatuzumab,,,,,,,,,1.8,1.8,,,,,,,,,,,,4.5,4.6,0.98,0.7-1.37,0.89,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
9447.0,KRAS,KRAS_G12 or KRAS_G13,55500243 + 55559231 + 55756103,,p.G12X + p.G13=,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Completed,NCT00079066,CO.17,PCD,2006Nov03,Yes,Yes,No benefit of treatment,1.0,18946061,,,Overall survival,151.0,75.0,76.0,FOLFIRI + Imgatuzumab,,,,,,,,,1.8,1.8,,,,,,,,,,,,4.5,4.6,0.98,0.7-1.37,0.89,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
9448.0,KRAS,KRAS_G12 or KRAS_G13,55500243 + 55559231 + 55756103,,p.G12X + p.G13=,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Completed,NCT00079066,CO.17,PCD,2006Nov03,Yes,Yes,No benefit of treatment,1.0,18946061,,,Overall survival,151.0,75.0,76.0,FOLFIRI + Imgatuzumab,,,,,,,,,1.8,1.8,,,,,,,,,,,,4.5,4.6,0.98,0.7-1.37,0.89,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
9449.0,KRAS,KRAS_G12 or KRAS_G13,55500243 + 55559231 + 55756103,,p.G12X + p.G13=,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Completed,NCT00079066,CO.17,PCD,2006Nov03,Yes,Yes,No benefit of treatment,1.0,18946061,,,Overall survival,151.0,75.0,76.0,FOLFIRI + Imgatuzumab,,,,,,,,,1.8,1.8,,,,,,,,,,,,4.5,4.6,0.98,0.7-1.37,0.89,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
9450.0,KRAS,KRAS_G12 or KRAS_G13,55500243 + 55559231 + 55756103,,p.G12X + p.G13=,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Completed,NCT00079066,CO.17,PCD,2006Nov03,Yes,Yes,No benefit of treatment,1.0,18946061,,,Overall survival,151.0,75.0,76.0,FOLFIRI + Imgatuzumab,,,,,,,,,1.8,1.8,,,,,,,,,,,,4.5,4.6,0.98,0.7-1.37,0.89,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
9451.0,KRAS,KRAS_G12 or KRAS_G13,55500243 + 55559231 + 55756103,,p.G12X + p.G13=,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Completed,NCT00079066,CO.17,PCD,2006Nov03,Yes,Yes,No benefit of treatment,1.0,18946061,,,Overall survival,151.0,75.0,76.0,FOLFIRI + Imgatuzumab,,,,,,,,,1.8,1.8,,,,,,,,,,,,4.5,4.6,0.98,0.7-1.37,0.89,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
9452.0,KRAS,KRAS_G12 or KRAS_G13,55500243 + 55559231 + 55756103,,p.G12X + p.G13=,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Completed,NCT00079066,CO.17,PCD,2006Nov03,Yes,Yes,No benefit of treatment,1.0,18946061,,,Overall survival,151.0,75.0,76.0,FOLFIRI + Imgatuzumab,,,,,,,,,1.8,1.8,,,,,,,,,,,,4.5,4.6,0.98,0.7-1.37,0.89,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
9453.0,KRAS,KRAS_G12 or KRAS_G13,55500243 + 55559231 + 55756103,,p.G12X + p.G13=,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Completed,NCT00079066,CO.17,PCD,2006Nov03,Yes,Yes,No benefit of treatment,1.0,18946061,,,Overall survival,151.0,75.0,76.0,FOLFIRI + Imgatuzumab,,,,,,,,,1.8,1.8,,,,,,,,,,,,4.5,4.6,0.98,0.7-1.37,0.89,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
9454.0,KRAS,KRAS_G12 or KRAS_G13,55500243 + 55559231 + 55756103,,p.G12X + p.G13=,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Completed,NCT00079066,CO.17,PCD,2006Nov03,Yes,Yes,No benefit of treatment,1.0,18946061,,,Overall survival,151.0,75.0,76.0,FOLFIRI + Imgatuzumab,,,,,,,,,1.8,1.8,,,,,,,,,,,,4.5,4.6,0.98,0.7-1.37,0.89,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
9455.0,KRAS,KRAS_G12 or KRAS_G13,55500243 + 55559231 + 55756103,,p.G12X + p.G13=,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Completed,NCT00079066,CO.17,PCD,2006Nov03,Yes,Yes,No benefit of treatment,1.0,18946061,,,Overall survival,151.0,75.0,76.0,FOLFIRI + Imgatuzumab,,,,,,,,,1.8,1.8,,,,,,,,,,,,4.5,4.6,0.98,0.7-1.37,0.89,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
9456.0,KRAS,KRAS_G12 or KRAS_G13,55500243 + 55559231 + 55756103,,p.G12X + p.G13=,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Completed,NCT00079066,CO.17,PCD,2006Nov03,Yes,Yes,No benefit of treatment,1.0,18946061,,,Overall survival,151.0,75.0,76.0,FOLFIRI + Imgatuzumab,,,,,,,,,1.8,1.8,,,,,,,,,,,,4.5,4.6,0.98,0.7-1.37,0.89,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
9457.0,KRAS,KRAS_G12 or KRAS_G13,55500243 + 55559231 + 55756103,,p.G12X + p.G13=,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Completed,NCT00079066,CO.17,PCD,2006Nov03,Yes,Yes,No benefit of treatment,1.0,18946061,,,Overall survival,151.0,75.0,76.0,FOLFIRI + Imgatuzumab,,,,,,,,,1.8,1.8,,,,,,,,,,,,4.5,4.6,0.98,0.7-1.37,0.89,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
9458.0,KRAS,KRAS_G12 or KRAS_G13,55500243 + 55559231 + 55756103,,p.G12X + p.G13=,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Completed,NCT00079066,CO.17,PCD,2006Nov03,Yes,Yes,No benefit of treatment,1.0,18946061,,,Overall survival,151.0,75.0,76.0,FOLFIRI + Imgatuzumab,,,,,,,,,1.8,1.8,,,,,,,,,,,,4.5,4.6,0.98,0.7-1.37,0.89,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
9459.0,KRAS,KRAS_G12 or KRAS_G13,55500243 + 55559231 + 55756103,,p.G12X + p.G13=,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Completed,NCT00079066,CO.17,PCD,2006Nov03,Yes,Yes,No benefit of treatment,1.0,18946061,,,Overall survival,151.0,75.0,76.0,FOLFIRI + Imgatuzumab,,,,,,,,,1.8,1.8,,,,,,,,,,,,4.5,4.6,0.98,0.7-1.37,0.89,,,,,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11715.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11716.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11717.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11718.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11719.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11720.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11721.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11722.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11723.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11724.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11725.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11726.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11727.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11728.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11729.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11730.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11731.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11732.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11733.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11734.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11735.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11736.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11737.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11738.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11739.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11740.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11741.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11742.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11743.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11744.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11745.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11746.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11747.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11748.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11749.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11750.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11751.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11752.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11753.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11754.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11755.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11756.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11757.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11758.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11759.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11760.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11761.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11762.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11763.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11764.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11765.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11766.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11767.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11768.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11769.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11770.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11771.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11772.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11773.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11774.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11775.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11776.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11777.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11778.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11779.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11780.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11781.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11782.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11783.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11784.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11785.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11786.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11787.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11788.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11789.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11790.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11791.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11792.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11793.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11794.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11795.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11796.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11797.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11798.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11799.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11800.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11801.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11802.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11803.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11804.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11805.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11806.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11807.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11808.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11809.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11810.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11811.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11812.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11813.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11814.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11815.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11816.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11817.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11818.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11819.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11820.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11821.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11822.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11823.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11824.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11825.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11826.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11827.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11828.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11829.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11830.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11831.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11832.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11833.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11834.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11835.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11836.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11837.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11838.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11839.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11840.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11841.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11842.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11843.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11844.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11845.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11846.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11847.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11848.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11849.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11850.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11851.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11852.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11853.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11854.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11855.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11856.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11857.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11858.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11859.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11860.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11861.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11862.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11863.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11864.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11865.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11866.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11867.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11868.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11869.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11870.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11871.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11872.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11873.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11874.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11875.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11876.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11877.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11878.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11879.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11880.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11881.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11882.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11883.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11884.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11885.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11886.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11887.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11888.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11889.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11890.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11891.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11892.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11893.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11894.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11895.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11896.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11897.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11898.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11899.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11900.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11901.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11902.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11903.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11904.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11905.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11906.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11907.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11908.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11909.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11910.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11911.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11912.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11913.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11914.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11915.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11916.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11917.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11918.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11919.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11920.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11921.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11922.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11923.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11924.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11925.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11926.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11927.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11928.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11929.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11930.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11931.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11932.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11933.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
11934.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12210.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12211.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12212.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12213.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12214.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12215.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12216.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12217.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12218.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12219.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12220.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12221.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12222.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12223.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12224.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12225.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12226.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12227.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12228.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12229.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12230.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12231.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12232.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12233.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12234.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12235.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12236.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12237.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12238.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12239.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12240.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12241.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12242.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12243.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12244.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12245.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12246.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12247.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12248.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12249.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12250.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12251.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12252.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12253.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12254.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12255.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12256.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12257.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12258.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12259.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12260.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12261.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12262.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12263.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
12264.0,KRAS,KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,2.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14575.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14576.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14577.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14578.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14579.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14580.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14581.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14582.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14583.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14584.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14585.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14586.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14587.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14588.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14589.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14590.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14591.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14592.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14593.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14594.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14595.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14596.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14597.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14598.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14599.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14600.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14601.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14602.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14603.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14604.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14605.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14606.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14607.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14608.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14609.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14610.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14611.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14612.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14613.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14614.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14615.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14616.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14617.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14618.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14619.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14620.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14621.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14622.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14623.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14624.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14625.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14626.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14627.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14628.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14629.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14630.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14631.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14632.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14633.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14634.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14635.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14636.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14637.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14638.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14639.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14640.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14641.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14642.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14643.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14644.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14645.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14646.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14647.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14648.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14649.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14650.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14651.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14652.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14653.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14654.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14655.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14656.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14657.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14658.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14659.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14660.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14661.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14662.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14663.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14664.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14665.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14666.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14667.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14668.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14669.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14670.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14671.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14672.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14673.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14674.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14675.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14676.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14677.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14678.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14679.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14680.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14681.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14682.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14683.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14684.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14685.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14686.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14687.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14688.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14689.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14690.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14691.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14692.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14693.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14694.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14695.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14696.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14697.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14698.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14699.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14700.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14701.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14702.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14703.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14704.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14705.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14706.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14707.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14708.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14709.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14710.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14711.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14712.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14713.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14714.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14715.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14716.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14717.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14718.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14719.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14720.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14721.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14722.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14723.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14724.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14725.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14726.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14727.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14728.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14729.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14730.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14731.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14732.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14733.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14734.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14735.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14736.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14737.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14738.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14739.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14740.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14741.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14742.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14743.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14744.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14745.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14746.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14747.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14748.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14749.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14750.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14751.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14752.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14753.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14754.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14755.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14756.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14757.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14758.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14759.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14760.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14761.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14762.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14763.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14764.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14765.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14766.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14767.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14768.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14769.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14770.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14771.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14772.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14773.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14774.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14775.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14776.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14777.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14778.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14779.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14780.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14781.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14782.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14783.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14784.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14785.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14786.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14787.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14788.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14789.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14790.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14791.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14792.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14793.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14794.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04189055,CETIDYL,ECD,2023Apr01,Yes,No,,4.0,NCT04189055,,,Response rate,72.0,72.0,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Nov01,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14795.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14796.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14797.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14798.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14799.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14800.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14801.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14802.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14803.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14804.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14805.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14806.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14807.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14808.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14809.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14810.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14811.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14812.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14813.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14814.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14815.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14816.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14817.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14818.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14819.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14820.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14821.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14822.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14823.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14824.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14825.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14826.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14827.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14828.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14829.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14830.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14831.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14832.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14833.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14834.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14835.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14836.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14837.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14838.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14839.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14840.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14841.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14842.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14843.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14844.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14845.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14846.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14847.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14848.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14849.0,NRAS,NRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14960.0,PIK3CA,PIK3CA_Exon20,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14961.0,PIK3CA,PIK3CA_Exon20,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14962.0,PIK3CA,PIK3CA_Exon20,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14963.0,PIK3CA,PIK3CA_Exon20,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14964.0,PIK3CA,PIK3CA_Exon20,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14965.0,PIK3CA,PIK3CA_Exon20,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14966.0,PIK3CA,PIK3CA_Exon20,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14967.0,PIK3CA,PIK3CA_Exon20,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14968.0,PIK3CA,PIK3CA_Exon20,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14969.0,PIK3CA,PIK3CA_Exon20,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14970.0,PIK3CA,PIK3CA_Exon20,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14971.0,PIK3CA,PIK3CA_Exon20,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14972.0,PIK3CA,PIK3CA_Exon20,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14973.0,PIK3CA,PIK3CA_Exon20,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14974.0,PIK3CA,PIK3CA_Exon20,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14975.0,PIK3CA,PIK3CA_Exon20,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14976.0,PIK3CA,PIK3CA_Exon20,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14977.0,PIK3CA,PIK3CA_Exon20,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14978.0,PIK3CA,PIK3CA_Exon20,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14979.0,PIK3CA,PIK3CA_Exon20,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14980.0,PIK3CA,PIK3CA_Exon20,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14981.0,PIK3CA,PIK3CA_Exon20,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14982.0,PIK3CA,PIK3CA_Exon20,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14983.0,PIK3CA,PIK3CA_Exon20,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14984.0,PIK3CA,PIK3CA_Exon20,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14985.0,PIK3CA,PIK3CA_Exon20,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14986.0,PIK3CA,PIK3CA_Exon20,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14987.0,PIK3CA,PIK3CA_Exon20,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14988.0,PIK3CA,PIK3CA_Exon20,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14989.0,PIK3CA,PIK3CA_Exon20,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14990.0,PIK3CA,PIK3CA_Exon20,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14991.0,PIK3CA,PIK3CA_Exon20,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14992.0,PIK3CA,PIK3CA_Exon20,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14993.0,PIK3CA,PIK3CA_Exon20,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14994.0,PIK3CA,PIK3CA_Exon20,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14995.0,PIK3CA,PIK3CA_Exon20,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14996.0,PIK3CA,PIK3CA_Exon20,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14997.0,PIK3CA,PIK3CA_Exon20,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14998.0,PIK3CA,PIK3CA_Exon20,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
14999.0,PIK3CA,PIK3CA_Exon20,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
15000.0,PIK3CA,PIK3CA_Exon20,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
15001.0,PIK3CA,PIK3CA_Exon20,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
15002.0,PIK3CA,PIK3CA_Exon20,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
15003.0,PIK3CA,PIK3CA_Exon20,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
15004.0,PIK3CA,PIK3CA_Exon20,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
15005.0,PIK3CA,PIK3CA_Exon20,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
15006.0,PIK3CA,PIK3CA_Exon20,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
15007.0,PIK3CA,PIK3CA_Exon20,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
15008.0,PIK3CA,PIK3CA_Exon20,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
15009.0,PIK3CA,PIK3CA_Exon20,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
15010.0,PIK3CA,PIK3CA_Exon20,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
15011.0,PIK3CA,PIK3CA_Exon20,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
15012.0,PIK3CA,PIK3CA_Exon20,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
15013.0,PIK3CA,PIK3CA_Exon20,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
15014.0,PIK3CA,PIK3CA_Exon20,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 3,Cetuximab,,Not yet recruiting,NCT02942706,BLOC-1,ECD,2022Oct01,Yes,No,,4.0,NCT02942706,,,Progression free survival,200.0,,,FOLFIRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Sep15,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16115.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16116.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16117.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16118.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16119.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16120.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16121.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16122.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16123.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16124.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16125.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16126.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16127.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16128.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16129.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16130.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16131.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16132.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16133.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16134.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16135.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16136.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16137.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16138.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16139.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16140.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16141.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16142.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16143.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16144.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16145.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16146.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16147.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16148.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16149.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16150.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16151.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16152.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16153.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16154.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16155.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16156.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16157.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16158.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16159.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16160.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16161.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16162.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16163.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16164.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16165.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16166.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16167.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16168.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16169.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16390.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16391.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16392.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16393.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16394.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16395.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16396.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16397.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16398.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16399.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16400.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16401.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16402.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16403.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16404.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16405.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16406.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16407.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16408.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16409.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16410.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16411.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16412.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16413.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16414.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16415.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16416.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16417.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16418.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16419.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16420.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16421.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16422.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16423.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16424.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16425.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16426.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16427.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16428.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16429.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16430.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16431.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16432.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16433.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16434.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16435.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16436.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16437.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16438.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16439.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16440.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16441.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16442.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16443.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16444.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16445.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16446.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16447.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16448.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16449.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16450.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16451.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16452.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16453.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16454.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16455.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16456.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16457.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16458.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16459.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16460.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16461.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16462.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16463.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16464.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16465.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16466.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16467.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16468.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16469.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16470.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16471.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16472.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16473.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16474.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16475.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16476.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16477.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16478.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16479.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16480.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16481.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16482.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16483.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16484.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16485.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16486.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16487.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16488.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16489.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16490.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16491.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16492.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16493.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16494.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16495.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16496.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16497.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16498.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16499.0,TP53,TP53_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Cetuximab,,Recruiting,NCT04853043,,ECD,2023Jul01,Yes,No,,4.0,NCT04853043,Previously-treated,,Progression free survival,21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Jan24,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
2970.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Terminated,NCT02175654,,PCD,2016Feb01,Yes,Yes,Slow accrual,4.0,NCT02175654,,,Progression free survival,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
2971.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Terminated,NCT02175654,,PCD,2016Feb01,Yes,Yes,Slow accrual,4.0,NCT02175654,,,Progression free survival,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
2972.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Terminated,NCT02175654,,PCD,2016Feb01,Yes,Yes,Slow accrual,4.0,NCT02175654,,,Progression free survival,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
2973.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Terminated,NCT02175654,,PCD,2016Feb01,Yes,Yes,Slow accrual,4.0,NCT02175654,,,Progression free survival,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
2974.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Terminated,NCT02175654,,PCD,2016Feb01,Yes,Yes,Slow accrual,4.0,NCT02175654,,,Progression free survival,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
2975.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Terminated,NCT02175654,,PCD,2016Feb01,Yes,Yes,Slow accrual,4.0,NCT02175654,,,Progression free survival,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
2976.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Terminated,NCT02175654,,PCD,2016Feb01,Yes,Yes,Slow accrual,4.0,NCT02175654,,,Progression free survival,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
2977.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Terminated,NCT02175654,,PCD,2016Feb01,Yes,Yes,Slow accrual,4.0,NCT02175654,,,Progression free survival,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
2978.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Terminated,NCT02175654,,PCD,2016Feb01,Yes,Yes,Slow accrual,4.0,NCT02175654,,,Progression free survival,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
2979.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Terminated,NCT02175654,,PCD,2016Feb01,Yes,Yes,Slow accrual,4.0,NCT02175654,,,Progression free survival,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
2980.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Terminated,NCT02175654,,PCD,2016Feb01,Yes,Yes,Slow accrual,4.0,NCT02175654,,,Progression free survival,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
2981.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Terminated,NCT02175654,,PCD,2016Feb01,Yes,Yes,Slow accrual,4.0,NCT02175654,,,Progression free survival,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
2982.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Terminated,NCT02175654,,PCD,2016Feb01,Yes,Yes,Slow accrual,4.0,NCT02175654,,,Progression free survival,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
2983.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Terminated,NCT02175654,,PCD,2016Feb01,Yes,Yes,Slow accrual,4.0,NCT02175654,,,Progression free survival,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
2984.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Terminated,NCT02175654,,PCD,2016Feb01,Yes,Yes,Slow accrual,4.0,NCT02175654,,,Progression free survival,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
2985.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Terminated,NCT02175654,,PCD,2016Feb01,Yes,Yes,Slow accrual,4.0,NCT02175654,,,Progression free survival,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
2986.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Terminated,NCT02175654,,PCD,2016Feb01,Yes,Yes,Slow accrual,4.0,NCT02175654,,,Progression free survival,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
2987.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Terminated,NCT02175654,,PCD,2016Feb01,Yes,Yes,Slow accrual,4.0,NCT02175654,,,Progression free survival,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
2988.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Terminated,NCT02175654,,PCD,2016Feb01,Yes,Yes,Slow accrual,4.0,NCT02175654,,,Progression free survival,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
2989.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Terminated,NCT02175654,,PCD,2016Feb01,Yes,Yes,Slow accrual,4.0,NCT02175654,,,Progression free survival,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
2990.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Terminated,NCT02175654,,PCD,2016Feb01,Yes,Yes,Slow accrual,4.0,NCT02175654,,,Progression free survival,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
2991.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Terminated,NCT02175654,,PCD,2016Feb01,Yes,Yes,Slow accrual,4.0,NCT02175654,,,Progression free survival,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
2992.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Terminated,NCT02175654,,PCD,2016Feb01,Yes,Yes,Slow accrual,4.0,NCT02175654,,,Progression free survival,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
2993.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Terminated,NCT02175654,,PCD,2016Feb01,Yes,Yes,Slow accrual,4.0,NCT02175654,,,Progression free survival,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
2994.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Terminated,NCT02175654,,PCD,2016Feb01,Yes,Yes,Slow accrual,4.0,NCT02175654,,,Progression free survival,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
2995.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Terminated,NCT02175654,,PCD,2016Feb01,Yes,Yes,Slow accrual,4.0,NCT02175654,,,Progression free survival,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
2996.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Terminated,NCT02175654,,PCD,2016Feb01,Yes,Yes,Slow accrual,4.0,NCT02175654,,,Progression free survival,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
2997.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Terminated,NCT02175654,,PCD,2016Feb01,Yes,Yes,Slow accrual,4.0,NCT02175654,,,Progression free survival,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
2998.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Terminated,NCT02175654,,PCD,2016Feb01,Yes,Yes,Slow accrual,4.0,NCT02175654,,,Progression free survival,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
2999.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Terminated,NCT02175654,,PCD,2016Feb01,Yes,Yes,Slow accrual,4.0,NCT02175654,,,Progression free survival,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
3000.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Terminated,NCT02175654,,PCD,2016Feb01,Yes,Yes,Slow accrual,4.0,NCT02175654,,,Progression free survival,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
3001.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Terminated,NCT02175654,,PCD,2016Feb01,Yes,Yes,Slow accrual,4.0,NCT02175654,,,Progression free survival,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
3002.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Terminated,NCT02175654,,PCD,2016Feb01,Yes,Yes,Slow accrual,4.0,NCT02175654,,,Progression free survival,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
3003.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Terminated,NCT02175654,,PCD,2016Feb01,Yes,Yes,Slow accrual,4.0,NCT02175654,,,Progression free survival,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
3004.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Terminated,NCT02175654,,PCD,2016Feb01,Yes,Yes,Slow accrual,4.0,NCT02175654,,,Progression free survival,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
3005.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Terminated,NCT02175654,,PCD,2016Feb01,Yes,Yes,Slow accrual,4.0,NCT02175654,,,Progression free survival,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
3006.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Terminated,NCT02175654,,PCD,2016Feb01,Yes,Yes,Slow accrual,4.0,NCT02175654,,,Progression free survival,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
3007.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Terminated,NCT02175654,,PCD,2016Feb01,Yes,Yes,Slow accrual,4.0,NCT02175654,,,Progression free survival,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
3008.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Terminated,NCT02175654,,PCD,2016Feb01,Yes,Yes,Slow accrual,4.0,NCT02175654,,,Progression free survival,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
3009.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Terminated,NCT02175654,,PCD,2016Feb01,Yes,Yes,Slow accrual,4.0,NCT02175654,,,Progression free survival,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
3010.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Terminated,NCT02175654,,PCD,2016Feb01,Yes,Yes,Slow accrual,4.0,NCT02175654,,,Progression free survival,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
3011.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Terminated,NCT02175654,,PCD,2016Feb01,Yes,Yes,Slow accrual,4.0,NCT02175654,,,Progression free survival,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
3012.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Terminated,NCT02175654,,PCD,2016Feb01,Yes,Yes,Slow accrual,4.0,NCT02175654,,,Progression free survival,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
3013.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Terminated,NCT02175654,,PCD,2016Feb01,Yes,Yes,Slow accrual,4.0,NCT02175654,,,Progression free survival,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
3014.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Terminated,NCT02175654,,PCD,2016Feb01,Yes,Yes,Slow accrual,4.0,NCT02175654,,,Progression free survival,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
3015.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Terminated,NCT02175654,,PCD,2016Feb01,Yes,Yes,Slow accrual,4.0,NCT02175654,,,Progression free survival,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
3016.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Terminated,NCT02175654,,PCD,2016Feb01,Yes,Yes,Slow accrual,4.0,NCT02175654,,,Progression free survival,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
3017.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Terminated,NCT02175654,,PCD,2016Feb01,Yes,Yes,Slow accrual,4.0,NCT02175654,,,Progression free survival,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
3018.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Terminated,NCT02175654,,PCD,2016Feb01,Yes,Yes,Slow accrual,4.0,NCT02175654,,,Progression free survival,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
3019.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Terminated,NCT02175654,,PCD,2016Feb01,Yes,Yes,Slow accrual,4.0,NCT02175654,,,Progression free survival,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
3020.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Terminated,NCT02175654,,PCD,2016Feb01,Yes,Yes,Slow accrual,4.0,NCT02175654,,,Progression free survival,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
3021.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Terminated,NCT02175654,,PCD,2016Feb01,Yes,Yes,Slow accrual,4.0,NCT02175654,,,Progression free survival,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
3022.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Terminated,NCT02175654,,PCD,2016Feb01,Yes,Yes,Slow accrual,4.0,NCT02175654,,,Progression free survival,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
3023.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Terminated,NCT02175654,,PCD,2016Feb01,Yes,Yes,Slow accrual,4.0,NCT02175654,,,Progression free survival,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
3024.0,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Terminated,NCT02175654,,PCD,2016Feb01,Yes,Yes,Slow accrual,4.0,NCT02175654,,,Progression free survival,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2021May18,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4125.0,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Recruiting,NCT05312398,CAPRI 2 GOIM,ECD,2025Aug15,Yes,No,,4.0,NCT05312398,,,Response rate,200.0,200.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022May19,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4126.0,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Recruiting,NCT05312398,CAPRI 2 GOIM,ECD,2025Aug15,Yes,No,,4.0,NCT05312398,,,Response rate,200.0,200.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022May19,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4127.0,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Recruiting,NCT05312398,CAPRI 2 GOIM,ECD,2025Aug15,Yes,No,,4.0,NCT05312398,,,Response rate,200.0,200.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022May19,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4128.0,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Recruiting,NCT05312398,CAPRI 2 GOIM,ECD,2025Aug15,Yes,No,,4.0,NCT05312398,,,Response rate,200.0,200.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022May19,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4129.0,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Recruiting,NCT05312398,CAPRI 2 GOIM,ECD,2025Aug15,Yes,No,,4.0,NCT05312398,,,Response rate,200.0,200.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022May19,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4130.0,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Recruiting,NCT05312398,CAPRI 2 GOIM,ECD,2025Aug15,Yes,No,,4.0,NCT05312398,,,Response rate,200.0,200.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022May19,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4131.0,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Recruiting,NCT05312398,CAPRI 2 GOIM,ECD,2025Aug15,Yes,No,,4.0,NCT05312398,,,Response rate,200.0,200.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022May19,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4132.0,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Recruiting,NCT05312398,CAPRI 2 GOIM,ECD,2025Aug15,Yes,No,,4.0,NCT05312398,,,Response rate,200.0,200.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022May19,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4133.0,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Recruiting,NCT05312398,CAPRI 2 GOIM,ECD,2025Aug15,Yes,No,,4.0,NCT05312398,,,Response rate,200.0,200.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022May19,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4134.0,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Recruiting,NCT05312398,CAPRI 2 GOIM,ECD,2025Aug15,Yes,No,,4.0,NCT05312398,,,Response rate,200.0,200.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022May19,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4135.0,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Recruiting,NCT05312398,CAPRI 2 GOIM,ECD,2025Aug15,Yes,No,,4.0,NCT05312398,,,Response rate,200.0,200.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022May19,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4136.0,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Recruiting,NCT05312398,CAPRI 2 GOIM,ECD,2025Aug15,Yes,No,,4.0,NCT05312398,,,Response rate,200.0,200.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022May19,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4137.0,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Recruiting,NCT05312398,CAPRI 2 GOIM,ECD,2025Aug15,Yes,No,,4.0,NCT05312398,,,Response rate,200.0,200.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022May19,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4138.0,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Recruiting,NCT05312398,CAPRI 2 GOIM,ECD,2025Aug15,Yes,No,,4.0,NCT05312398,,,Response rate,200.0,200.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022May19,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4139.0,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Recruiting,NCT05312398,CAPRI 2 GOIM,ECD,2025Aug15,Yes,No,,4.0,NCT05312398,,,Response rate,200.0,200.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022May19,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4140.0,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Recruiting,NCT05312398,CAPRI 2 GOIM,ECD,2025Aug15,Yes,No,,4.0,NCT05312398,,,Response rate,200.0,200.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022May19,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4141.0,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Recruiting,NCT05312398,CAPRI 2 GOIM,ECD,2025Aug15,Yes,No,,4.0,NCT05312398,,,Response rate,200.0,200.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022May19,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4142.0,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Recruiting,NCT05312398,CAPRI 2 GOIM,ECD,2025Aug15,Yes,No,,4.0,NCT05312398,,,Response rate,200.0,200.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022May19,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4143.0,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Recruiting,NCT05312398,CAPRI 2 GOIM,ECD,2025Aug15,Yes,No,,4.0,NCT05312398,,,Response rate,200.0,200.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022May19,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4144.0,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Recruiting,NCT05312398,CAPRI 2 GOIM,ECD,2025Aug15,Yes,No,,4.0,NCT05312398,,,Response rate,200.0,200.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022May19,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4145.0,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Recruiting,NCT05312398,CAPRI 2 GOIM,ECD,2025Aug15,Yes,No,,4.0,NCT05312398,,,Response rate,200.0,200.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022May19,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4146.0,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Recruiting,NCT05312398,CAPRI 2 GOIM,ECD,2025Aug15,Yes,No,,4.0,NCT05312398,,,Response rate,200.0,200.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022May19,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4147.0,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Recruiting,NCT05312398,CAPRI 2 GOIM,ECD,2025Aug15,Yes,No,,4.0,NCT05312398,,,Response rate,200.0,200.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022May19,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4148.0,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Recruiting,NCT05312398,CAPRI 2 GOIM,ECD,2025Aug15,Yes,No,,4.0,NCT05312398,,,Response rate,200.0,200.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022May19,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4149.0,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Recruiting,NCT05312398,CAPRI 2 GOIM,ECD,2025Aug15,Yes,No,,4.0,NCT05312398,,,Response rate,200.0,200.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022May19,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4150.0,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Recruiting,NCT05312398,CAPRI 2 GOIM,ECD,2025Aug15,Yes,No,,4.0,NCT05312398,,,Response rate,200.0,200.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022May19,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4151.0,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Recruiting,NCT05312398,CAPRI 2 GOIM,ECD,2025Aug15,Yes,No,,4.0,NCT05312398,,,Response rate,200.0,200.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022May19,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4152.0,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Recruiting,NCT05312398,CAPRI 2 GOIM,ECD,2025Aug15,Yes,No,,4.0,NCT05312398,,,Response rate,200.0,200.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022May19,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4153.0,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Recruiting,NCT05312398,CAPRI 2 GOIM,ECD,2025Aug15,Yes,No,,4.0,NCT05312398,,,Response rate,200.0,200.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022May19,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4154.0,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Recruiting,NCT05312398,CAPRI 2 GOIM,ECD,2025Aug15,Yes,No,,4.0,NCT05312398,,,Response rate,200.0,200.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022May19,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4155.0,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Recruiting,NCT05312398,CAPRI 2 GOIM,ECD,2025Aug15,Yes,No,,4.0,NCT05312398,,,Response rate,200.0,200.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022May19,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4156.0,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Recruiting,NCT05312398,CAPRI 2 GOIM,ECD,2025Aug15,Yes,No,,4.0,NCT05312398,,,Response rate,200.0,200.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022May19,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4157.0,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Recruiting,NCT05312398,CAPRI 2 GOIM,ECD,2025Aug15,Yes,No,,4.0,NCT05312398,,,Response rate,200.0,200.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022May19,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4158.0,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Recruiting,NCT05312398,CAPRI 2 GOIM,ECD,2025Aug15,Yes,No,,4.0,NCT05312398,,,Response rate,200.0,200.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022May19,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4159.0,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Recruiting,NCT05312398,CAPRI 2 GOIM,ECD,2025Aug15,Yes,No,,4.0,NCT05312398,,,Response rate,200.0,200.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022May19,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4160.0,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Recruiting,NCT05312398,CAPRI 2 GOIM,ECD,2025Aug15,Yes,No,,4.0,NCT05312398,,,Response rate,200.0,200.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022May19,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4161.0,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Recruiting,NCT05312398,CAPRI 2 GOIM,ECD,2025Aug15,Yes,No,,4.0,NCT05312398,,,Response rate,200.0,200.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022May19,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4162.0,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Recruiting,NCT05312398,CAPRI 2 GOIM,ECD,2025Aug15,Yes,No,,4.0,NCT05312398,,,Response rate,200.0,200.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022May19,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4163.0,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Recruiting,NCT05312398,CAPRI 2 GOIM,ECD,2025Aug15,Yes,No,,4.0,NCT05312398,,,Response rate,200.0,200.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022May19,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4164.0,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Recruiting,NCT05312398,CAPRI 2 GOIM,ECD,2025Aug15,Yes,No,,4.0,NCT05312398,,,Response rate,200.0,200.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022May19,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4165.0,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Recruiting,NCT05312398,CAPRI 2 GOIM,ECD,2025Aug15,Yes,No,,4.0,NCT05312398,,,Response rate,200.0,200.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022May19,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4166.0,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Recruiting,NCT05312398,CAPRI 2 GOIM,ECD,2025Aug15,Yes,No,,4.0,NCT05312398,,,Response rate,200.0,200.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022May19,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4167.0,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Recruiting,NCT05312398,CAPRI 2 GOIM,ECD,2025Aug15,Yes,No,,4.0,NCT05312398,,,Response rate,200.0,200.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022May19,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4168.0,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Recruiting,NCT05312398,CAPRI 2 GOIM,ECD,2025Aug15,Yes,No,,4.0,NCT05312398,,,Response rate,200.0,200.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022May19,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4169.0,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Recruiting,NCT05312398,CAPRI 2 GOIM,ECD,2025Aug15,Yes,No,,4.0,NCT05312398,,,Response rate,200.0,200.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022May19,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4170.0,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Recruiting,NCT05312398,CAPRI 2 GOIM,ECD,2025Aug15,Yes,No,,4.0,NCT05312398,,,Response rate,200.0,200.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022May19,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4171.0,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Recruiting,NCT05312398,CAPRI 2 GOIM,ECD,2025Aug15,Yes,No,,4.0,NCT05312398,,,Response rate,200.0,200.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022May19,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4172.0,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Recruiting,NCT05312398,CAPRI 2 GOIM,ECD,2025Aug15,Yes,No,,4.0,NCT05312398,,,Response rate,200.0,200.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022May19,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4173.0,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Recruiting,NCT05312398,CAPRI 2 GOIM,ECD,2025Aug15,Yes,No,,4.0,NCT05312398,,,Response rate,200.0,200.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022May19,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4174.0,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Recruiting,NCT05312398,CAPRI 2 GOIM,ECD,2025Aug15,Yes,No,,4.0,NCT05312398,,,Response rate,200.0,200.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022May19,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4175.0,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Recruiting,NCT05312398,CAPRI 2 GOIM,ECD,2025Aug15,Yes,No,,4.0,NCT05312398,,,Response rate,200.0,200.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022May19,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4176.0,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Recruiting,NCT05312398,CAPRI 2 GOIM,ECD,2025Aug15,Yes,No,,4.0,NCT05312398,,,Response rate,200.0,200.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022May19,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4177.0,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Recruiting,NCT05312398,CAPRI 2 GOIM,ECD,2025Aug15,Yes,No,,4.0,NCT05312398,,,Response rate,200.0,200.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022May19,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4178.0,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Recruiting,NCT05312398,CAPRI 2 GOIM,ECD,2025Aug15,Yes,No,,4.0,NCT05312398,,,Response rate,200.0,200.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022May19,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
4179.0,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Regorafenib,,Recruiting,NCT05312398,CAPRI 2 GOIM,ECD,2025Aug15,Yes,No,,4.0,NCT05312398,,,Response rate,200.0,200.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022May19,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5610.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Phase 2,Regorafenib,,"Active, not recruiting",NCT03992456,PULSE,ECD,2022Dec31,No,No,,4.0,NCT03992456,,,Overall survival,120.0,120.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5611.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Phase 2,Regorafenib,,"Active, not recruiting",NCT03992456,PULSE,ECD,2022Dec31,No,No,,4.0,NCT03992456,,,Overall survival,120.0,120.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5612.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Phase 2,Regorafenib,,"Active, not recruiting",NCT03992456,PULSE,ECD,2022Dec31,No,No,,4.0,NCT03992456,,,Overall survival,120.0,120.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5613.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Phase 2,Regorafenib,,"Active, not recruiting",NCT03992456,PULSE,ECD,2022Dec31,No,No,,4.0,NCT03992456,,,Overall survival,120.0,120.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5614.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Phase 2,Regorafenib,,"Active, not recruiting",NCT03992456,PULSE,ECD,2022Dec31,No,No,,4.0,NCT03992456,,,Overall survival,120.0,120.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5615.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Phase 2,Regorafenib,,"Active, not recruiting",NCT03992456,PULSE,ECD,2022Dec31,No,No,,4.0,NCT03992456,,,Overall survival,120.0,120.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5616.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Phase 2,Regorafenib,,"Active, not recruiting",NCT03992456,PULSE,ECD,2022Dec31,No,No,,4.0,NCT03992456,,,Overall survival,120.0,120.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5617.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Phase 2,Regorafenib,,"Active, not recruiting",NCT03992456,PULSE,ECD,2022Dec31,No,No,,4.0,NCT03992456,,,Overall survival,120.0,120.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5618.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Phase 2,Regorafenib,,"Active, not recruiting",NCT03992456,PULSE,ECD,2022Dec31,No,No,,4.0,NCT03992456,,,Overall survival,120.0,120.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5619.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Phase 2,Regorafenib,,"Active, not recruiting",NCT03992456,PULSE,ECD,2022Dec31,No,No,,4.0,NCT03992456,,,Overall survival,120.0,120.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5620.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Phase 2,Regorafenib,,"Active, not recruiting",NCT03992456,PULSE,ECD,2022Dec31,No,No,,4.0,NCT03992456,,,Overall survival,120.0,120.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5621.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Phase 2,Regorafenib,,"Active, not recruiting",NCT03992456,PULSE,ECD,2022Dec31,No,No,,4.0,NCT03992456,,,Overall survival,120.0,120.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5622.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Phase 2,Regorafenib,,"Active, not recruiting",NCT03992456,PULSE,ECD,2022Dec31,No,No,,4.0,NCT03992456,,,Overall survival,120.0,120.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5623.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Phase 2,Regorafenib,,"Active, not recruiting",NCT03992456,PULSE,ECD,2022Dec31,No,No,,4.0,NCT03992456,,,Overall survival,120.0,120.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5624.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Phase 2,Regorafenib,,"Active, not recruiting",NCT03992456,PULSE,ECD,2022Dec31,No,No,,4.0,NCT03992456,,,Overall survival,120.0,120.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5625.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Phase 2,Regorafenib,,"Active, not recruiting",NCT03992456,PULSE,ECD,2022Dec31,No,No,,4.0,NCT03992456,,,Overall survival,120.0,120.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5626.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Phase 2,Regorafenib,,"Active, not recruiting",NCT03992456,PULSE,ECD,2022Dec31,No,No,,4.0,NCT03992456,,,Overall survival,120.0,120.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5627.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Phase 2,Regorafenib,,"Active, not recruiting",NCT03992456,PULSE,ECD,2022Dec31,No,No,,4.0,NCT03992456,,,Overall survival,120.0,120.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5628.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Phase 2,Regorafenib,,"Active, not recruiting",NCT03992456,PULSE,ECD,2022Dec31,No,No,,4.0,NCT03992456,,,Overall survival,120.0,120.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5629.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Phase 2,Regorafenib,,"Active, not recruiting",NCT03992456,PULSE,ECD,2022Dec31,No,No,,4.0,NCT03992456,,,Overall survival,120.0,120.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5630.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Phase 2,Regorafenib,,"Active, not recruiting",NCT03992456,PULSE,ECD,2022Dec31,No,No,,4.0,NCT03992456,,,Overall survival,120.0,120.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5631.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Phase 2,Regorafenib,,"Active, not recruiting",NCT03992456,PULSE,ECD,2022Dec31,No,No,,4.0,NCT03992456,,,Overall survival,120.0,120.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5632.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Phase 2,Regorafenib,,"Active, not recruiting",NCT03992456,PULSE,ECD,2022Dec31,No,No,,4.0,NCT03992456,,,Overall survival,120.0,120.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5633.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Phase 2,Regorafenib,,"Active, not recruiting",NCT03992456,PULSE,ECD,2022Dec31,No,No,,4.0,NCT03992456,,,Overall survival,120.0,120.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5634.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Phase 2,Regorafenib,,"Active, not recruiting",NCT03992456,PULSE,ECD,2022Dec31,No,No,,4.0,NCT03992456,,,Overall survival,120.0,120.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5635.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Phase 2,Regorafenib,,"Active, not recruiting",NCT03992456,PULSE,ECD,2022Dec31,No,No,,4.0,NCT03992456,,,Overall survival,120.0,120.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5636.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Phase 2,Regorafenib,,"Active, not recruiting",NCT03992456,PULSE,ECD,2022Dec31,No,No,,4.0,NCT03992456,,,Overall survival,120.0,120.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5637.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Phase 2,Regorafenib,,"Active, not recruiting",NCT03992456,PULSE,ECD,2022Dec31,No,No,,4.0,NCT03992456,,,Overall survival,120.0,120.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5638.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Phase 2,Regorafenib,,"Active, not recruiting",NCT03992456,PULSE,ECD,2022Dec31,No,No,,4.0,NCT03992456,,,Overall survival,120.0,120.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5639.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Phase 2,Regorafenib,,"Active, not recruiting",NCT03992456,PULSE,ECD,2022Dec31,No,No,,4.0,NCT03992456,,,Overall survival,120.0,120.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5640.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Phase 2,Regorafenib,,"Active, not recruiting",NCT03992456,PULSE,ECD,2022Dec31,No,No,,4.0,NCT03992456,,,Overall survival,120.0,120.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5641.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Phase 2,Regorafenib,,"Active, not recruiting",NCT03992456,PULSE,ECD,2022Dec31,No,No,,4.0,NCT03992456,,,Overall survival,120.0,120.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5642.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Phase 2,Regorafenib,,"Active, not recruiting",NCT03992456,PULSE,ECD,2022Dec31,No,No,,4.0,NCT03992456,,,Overall survival,120.0,120.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5643.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Phase 2,Regorafenib,,"Active, not recruiting",NCT03992456,PULSE,ECD,2022Dec31,No,No,,4.0,NCT03992456,,,Overall survival,120.0,120.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5644.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Phase 2,Regorafenib,,"Active, not recruiting",NCT03992456,PULSE,ECD,2022Dec31,No,No,,4.0,NCT03992456,,,Overall survival,120.0,120.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5645.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Phase 2,Regorafenib,,"Active, not recruiting",NCT03992456,PULSE,ECD,2022Dec31,No,No,,4.0,NCT03992456,,,Overall survival,120.0,120.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5646.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Phase 2,Regorafenib,,"Active, not recruiting",NCT03992456,PULSE,ECD,2022Dec31,No,No,,4.0,NCT03992456,,,Overall survival,120.0,120.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5647.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Phase 2,Regorafenib,,"Active, not recruiting",NCT03992456,PULSE,ECD,2022Dec31,No,No,,4.0,NCT03992456,,,Overall survival,120.0,120.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5648.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Phase 2,Regorafenib,,"Active, not recruiting",NCT03992456,PULSE,ECD,2022Dec31,No,No,,4.0,NCT03992456,,,Overall survival,120.0,120.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5649.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Phase 2,Regorafenib,,"Active, not recruiting",NCT03992456,PULSE,ECD,2022Dec31,No,No,,4.0,NCT03992456,,,Overall survival,120.0,120.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5650.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Phase 2,Regorafenib,,"Active, not recruiting",NCT03992456,PULSE,ECD,2022Dec31,No,No,,4.0,NCT03992456,,,Overall survival,120.0,120.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5651.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Phase 2,Regorafenib,,"Active, not recruiting",NCT03992456,PULSE,ECD,2022Dec31,No,No,,4.0,NCT03992456,,,Overall survival,120.0,120.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5652.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Phase 2,Regorafenib,,"Active, not recruiting",NCT03992456,PULSE,ECD,2022Dec31,No,No,,4.0,NCT03992456,,,Overall survival,120.0,120.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5653.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Phase 2,Regorafenib,,"Active, not recruiting",NCT03992456,PULSE,ECD,2022Dec31,No,No,,4.0,NCT03992456,,,Overall survival,120.0,120.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5654.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Phase 2,Regorafenib,,"Active, not recruiting",NCT03992456,PULSE,ECD,2022Dec31,No,No,,4.0,NCT03992456,,,Overall survival,120.0,120.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5655.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Phase 2,Regorafenib,,"Active, not recruiting",NCT03992456,PULSE,ECD,2022Dec31,No,No,,4.0,NCT03992456,,,Overall survival,120.0,120.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5656.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Phase 2,Regorafenib,,"Active, not recruiting",NCT03992456,PULSE,ECD,2022Dec31,No,No,,4.0,NCT03992456,,,Overall survival,120.0,120.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5657.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Phase 2,Regorafenib,,"Active, not recruiting",NCT03992456,PULSE,ECD,2022Dec31,No,No,,4.0,NCT03992456,,,Overall survival,120.0,120.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5658.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Phase 2,Regorafenib,,"Active, not recruiting",NCT03992456,PULSE,ECD,2022Dec31,No,No,,4.0,NCT03992456,,,Overall survival,120.0,120.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5659.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Phase 2,Regorafenib,,"Active, not recruiting",NCT03992456,PULSE,ECD,2022Dec31,No,No,,4.0,NCT03992456,,,Overall survival,120.0,120.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5660.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Phase 2,Regorafenib,,"Active, not recruiting",NCT03992456,PULSE,ECD,2022Dec31,No,No,,4.0,NCT03992456,,,Overall survival,120.0,120.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5661.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Phase 2,Regorafenib,,"Active, not recruiting",NCT03992456,PULSE,ECD,2022Dec31,No,No,,4.0,NCT03992456,,,Overall survival,120.0,120.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5662.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Phase 2,Regorafenib,,"Active, not recruiting",NCT03992456,PULSE,ECD,2022Dec31,No,No,,4.0,NCT03992456,,,Overall survival,120.0,120.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5663.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Phase 2,Regorafenib,,"Active, not recruiting",NCT03992456,PULSE,ECD,2022Dec31,No,No,,4.0,NCT03992456,,,Overall survival,120.0,120.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
5664.0,EGFR,EGFR_unspecified,,,,large intestine / carcinoma / adenocarcinoma,1.0,Phase 2,Regorafenib,,"Active, not recruiting",NCT03992456,PULSE,ECD,2022Dec31,No,No,,4.0,NCT03992456,,,Overall survival,120.0,120.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28864826,2022Aug04,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
8800.0,FLT3,FLT3_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Sunitinib,,Recruiting,NCT02693535,TAPUR,ECD,2024Dec31,Expression confirmed,Yes,,2.0,10.1007/s11523-020-00752-8,,,Overall Response Rate,3581.0,3581.0,,,0.0,,,,,,,,2.33,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
8801.0,FLT3,FLT3_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Sunitinib,,Recruiting,NCT02693535,TAPUR,ECD,2024Dec31,Expression confirmed,Yes,,2.0,10.1007/s11523-020-00752-8,,,Overall Response Rate,3581.0,3581.0,,,0.0,,,,,,,,2.33,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
8802.0,FLT3,FLT3_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Sunitinib,,Recruiting,NCT02693535,TAPUR,ECD,2024Dec31,Expression confirmed,Yes,,2.0,10.1007/s11523-020-00752-8,,,Overall Response Rate,3581.0,3581.0,,,0.0,,,,,,,,2.33,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
8803.0,FLT3,FLT3_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Sunitinib,,Recruiting,NCT02693535,TAPUR,ECD,2024Dec31,Expression confirmed,Yes,,2.0,10.1007/s11523-020-00752-8,,,Overall Response Rate,3581.0,3581.0,,,0.0,,,,,,,,2.33,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
8804.0,FLT3,FLT3_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Sunitinib,,Recruiting,NCT02693535,TAPUR,ECD,2024Dec31,Expression confirmed,Yes,,2.0,10.1007/s11523-020-00752-8,,,Overall Response Rate,3581.0,3581.0,,,0.0,,,,,,,,2.33,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
8805.0,FLT3,FLT3_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Sunitinib,,Recruiting,NCT02693535,TAPUR,ECD,2024Dec31,Expression confirmed,Yes,,2.0,10.1007/s11523-020-00752-8,,,Overall Response Rate,3581.0,3581.0,,,0.0,,,,,,,,2.33,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
8806.0,FLT3,FLT3_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Sunitinib,,Recruiting,NCT02693535,TAPUR,ECD,2024Dec31,Expression confirmed,Yes,,2.0,10.1007/s11523-020-00752-8,,,Overall Response Rate,3581.0,3581.0,,,0.0,,,,,,,,2.33,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
8807.0,FLT3,FLT3_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Sunitinib,,Recruiting,NCT02693535,TAPUR,ECD,2024Dec31,Expression confirmed,Yes,,2.0,10.1007/s11523-020-00752-8,,,Overall Response Rate,3581.0,3581.0,,,0.0,,,,,,,,2.33,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
8808.0,FLT3,FLT3_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Sunitinib,,Recruiting,NCT02693535,TAPUR,ECD,2024Dec31,Expression confirmed,Yes,,2.0,10.1007/s11523-020-00752-8,,,Overall Response Rate,3581.0,3581.0,,,0.0,,,,,,,,2.33,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
8809.0,FLT3,FLT3_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Sunitinib,,Recruiting,NCT02693535,TAPUR,ECD,2024Dec31,Expression confirmed,Yes,,2.0,10.1007/s11523-020-00752-8,,,Overall Response Rate,3581.0,3581.0,,,0.0,,,,,,,,2.33,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
8810.0,FLT3,FLT3_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Sunitinib,,Recruiting,NCT02693535,TAPUR,ECD,2024Dec31,Expression confirmed,Yes,,2.0,10.1007/s11523-020-00752-8,,,Overall Response Rate,3581.0,3581.0,,,0.0,,,,,,,,2.33,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
8811.0,FLT3,FLT3_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Sunitinib,,Recruiting,NCT02693535,TAPUR,ECD,2024Dec31,Expression confirmed,Yes,,2.0,10.1007/s11523-020-00752-8,,,Overall Response Rate,3581.0,3581.0,,,0.0,,,,,,,,2.33,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
8812.0,FLT3,FLT3_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Sunitinib,,Recruiting,NCT02693535,TAPUR,ECD,2024Dec31,Expression confirmed,Yes,,2.0,10.1007/s11523-020-00752-8,,,Overall Response Rate,3581.0,3581.0,,,0.0,,,,,,,,2.33,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
8813.0,FLT3,FLT3_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Sunitinib,,Recruiting,NCT02693535,TAPUR,ECD,2024Dec31,Expression confirmed,Yes,,2.0,10.1007/s11523-020-00752-8,,,Overall Response Rate,3581.0,3581.0,,,0.0,,,,,,,,2.33,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
8814.0,FLT3,FLT3_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Sunitinib,,Recruiting,NCT02693535,TAPUR,ECD,2024Dec31,Expression confirmed,Yes,,2.0,10.1007/s11523-020-00752-8,,,Overall Response Rate,3581.0,3581.0,,,0.0,,,,,,,,2.33,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
8815.0,FLT3,FLT3_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Sunitinib,,Recruiting,NCT02693535,TAPUR,ECD,2024Dec31,Expression confirmed,Yes,,2.0,10.1007/s11523-020-00752-8,,,Overall Response Rate,3581.0,3581.0,,,0.0,,,,,,,,2.33,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
8816.0,FLT3,FLT3_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Sunitinib,,Recruiting,NCT02693535,TAPUR,ECD,2024Dec31,Expression confirmed,Yes,,2.0,10.1007/s11523-020-00752-8,,,Overall Response Rate,3581.0,3581.0,,,0.0,,,,,,,,2.33,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
8817.0,FLT3,FLT3_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Sunitinib,,Recruiting,NCT02693535,TAPUR,ECD,2024Dec31,Expression confirmed,Yes,,2.0,10.1007/s11523-020-00752-8,,,Overall Response Rate,3581.0,3581.0,,,0.0,,,,,,,,2.33,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
8818.0,FLT3,FLT3_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Sunitinib,,Recruiting,NCT02693535,TAPUR,ECD,2024Dec31,Expression confirmed,Yes,,2.0,10.1007/s11523-020-00752-8,,,Overall Response Rate,3581.0,3581.0,,,0.0,,,,,,,,2.33,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
8819.0,FLT3,FLT3_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Sunitinib,,Recruiting,NCT02693535,TAPUR,ECD,2024Dec31,Expression confirmed,Yes,,2.0,10.1007/s11523-020-00752-8,,,Overall Response Rate,3581.0,3581.0,,,0.0,,,,,,,,2.33,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
8820.0,FLT3,FLT3_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Sunitinib,,Recruiting,NCT02693535,TAPUR,ECD,2024Dec31,Expression confirmed,Yes,,2.0,10.1007/s11523-020-00752-8,,,Overall Response Rate,3581.0,3581.0,,,0.0,,,,,,,,2.33,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
8821.0,FLT3,FLT3_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Sunitinib,,Recruiting,NCT02693535,TAPUR,ECD,2024Dec31,Expression confirmed,Yes,,2.0,10.1007/s11523-020-00752-8,,,Overall Response Rate,3581.0,3581.0,,,0.0,,,,,,,,2.33,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
8822.0,FLT3,FLT3_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Sunitinib,,Recruiting,NCT02693535,TAPUR,ECD,2024Dec31,Expression confirmed,Yes,,2.0,10.1007/s11523-020-00752-8,,,Overall Response Rate,3581.0,3581.0,,,0.0,,,,,,,,2.33,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
8823.0,FLT3,FLT3_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Sunitinib,,Recruiting,NCT02693535,TAPUR,ECD,2024Dec31,Expression confirmed,Yes,,2.0,10.1007/s11523-020-00752-8,,,Overall Response Rate,3581.0,3581.0,,,0.0,,,,,,,,2.33,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
8824.0,FLT3,FLT3_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Sunitinib,,Recruiting,NCT02693535,TAPUR,ECD,2024Dec31,Expression confirmed,Yes,,2.0,10.1007/s11523-020-00752-8,,,Overall Response Rate,3581.0,3581.0,,,0.0,,,,,,,,2.33,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
8825.0,FLT3,FLT3_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Sunitinib,,Recruiting,NCT02693535,TAPUR,ECD,2024Dec31,Expression confirmed,Yes,,2.0,10.1007/s11523-020-00752-8,,,Overall Response Rate,3581.0,3581.0,,,0.0,,,,,,,,2.33,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
8826.0,FLT3,FLT3_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Sunitinib,,Recruiting,NCT02693535,TAPUR,ECD,2024Dec31,Expression confirmed,Yes,,2.0,10.1007/s11523-020-00752-8,,,Overall Response Rate,3581.0,3581.0,,,0.0,,,,,,,,2.33,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
8827.0,FLT3,FLT3_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Sunitinib,,Recruiting,NCT02693535,TAPUR,ECD,2024Dec31,Expression confirmed,Yes,,2.0,10.1007/s11523-020-00752-8,,,Overall Response Rate,3581.0,3581.0,,,0.0,,,,,,,,2.33,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
8828.0,FLT3,FLT3_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Sunitinib,,Recruiting,NCT02693535,TAPUR,ECD,2024Dec31,Expression confirmed,Yes,,2.0,10.1007/s11523-020-00752-8,,,Overall Response Rate,3581.0,3581.0,,,0.0,,,,,,,,2.33,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
8829.0,FLT3,FLT3_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Sunitinib,,Recruiting,NCT02693535,TAPUR,ECD,2024Dec31,Expression confirmed,Yes,,2.0,10.1007/s11523-020-00752-8,,,Overall Response Rate,3581.0,3581.0,,,0.0,,,,,,,,2.33,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
8830.0,FLT3,FLT3_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Sunitinib,,Recruiting,NCT02693535,TAPUR,ECD,2024Dec31,Expression confirmed,Yes,,2.0,10.1007/s11523-020-00752-8,,,Overall Response Rate,3581.0,3581.0,,,0.0,,,,,,,,2.33,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
8831.0,FLT3,FLT3_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Sunitinib,,Recruiting,NCT02693535,TAPUR,ECD,2024Dec31,Expression confirmed,Yes,,2.0,10.1007/s11523-020-00752-8,,,Overall Response Rate,3581.0,3581.0,,,0.0,,,,,,,,2.33,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
8832.0,FLT3,FLT3_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Sunitinib,,Recruiting,NCT02693535,TAPUR,ECD,2024Dec31,Expression confirmed,Yes,,2.0,10.1007/s11523-020-00752-8,,,Overall Response Rate,3581.0,3581.0,,,0.0,,,,,,,,2.33,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
8833.0,FLT3,FLT3_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Sunitinib,,Recruiting,NCT02693535,TAPUR,ECD,2024Dec31,Expression confirmed,Yes,,2.0,10.1007/s11523-020-00752-8,,,Overall Response Rate,3581.0,3581.0,,,0.0,,,,,,,,2.33,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
8834.0,FLT3,FLT3_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Sunitinib,,Recruiting,NCT02693535,TAPUR,ECD,2024Dec31,Expression confirmed,Yes,,2.0,10.1007/s11523-020-00752-8,,,Overall Response Rate,3581.0,3581.0,,,0.0,,,,,,,,2.33,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
8835.0,FLT3,FLT3_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Sunitinib,,Recruiting,NCT02693535,TAPUR,ECD,2024Dec31,Expression confirmed,Yes,,2.0,10.1007/s11523-020-00752-8,,,Overall Response Rate,3581.0,3581.0,,,0.0,,,,,,,,2.33,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
8836.0,FLT3,FLT3_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Sunitinib,,Recruiting,NCT02693535,TAPUR,ECD,2024Dec31,Expression confirmed,Yes,,2.0,10.1007/s11523-020-00752-8,,,Overall Response Rate,3581.0,3581.0,,,0.0,,,,,,,,2.33,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
8837.0,FLT3,FLT3_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Sunitinib,,Recruiting,NCT02693535,TAPUR,ECD,2024Dec31,Expression confirmed,Yes,,2.0,10.1007/s11523-020-00752-8,,,Overall Response Rate,3581.0,3581.0,,,0.0,,,,,,,,2.33,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
8838.0,FLT3,FLT3_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Sunitinib,,Recruiting,NCT02693535,TAPUR,ECD,2024Dec31,Expression confirmed,Yes,,2.0,10.1007/s11523-020-00752-8,,,Overall Response Rate,3581.0,3581.0,,,0.0,,,,,,,,2.33,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
8839.0,FLT3,FLT3_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Sunitinib,,Recruiting,NCT02693535,TAPUR,ECD,2024Dec31,Expression confirmed,Yes,,2.0,10.1007/s11523-020-00752-8,,,Overall Response Rate,3581.0,3581.0,,,0.0,,,,,,,,2.33,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
8840.0,FLT3,FLT3_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Sunitinib,,Recruiting,NCT02693535,TAPUR,ECD,2024Dec31,Expression confirmed,Yes,,2.0,10.1007/s11523-020-00752-8,,,Overall Response Rate,3581.0,3581.0,,,0.0,,,,,,,,2.33,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
8841.0,FLT3,FLT3_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Sunitinib,,Recruiting,NCT02693535,TAPUR,ECD,2024Dec31,Expression confirmed,Yes,,2.0,10.1007/s11523-020-00752-8,,,Overall Response Rate,3581.0,3581.0,,,0.0,,,,,,,,2.33,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
8842.0,FLT3,FLT3_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Sunitinib,,Recruiting,NCT02693535,TAPUR,ECD,2024Dec31,Expression confirmed,Yes,,2.0,10.1007/s11523-020-00752-8,,,Overall Response Rate,3581.0,3581.0,,,0.0,,,,,,,,2.33,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
8843.0,FLT3,FLT3_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Sunitinib,,Recruiting,NCT02693535,TAPUR,ECD,2024Dec31,Expression confirmed,Yes,,2.0,10.1007/s11523-020-00752-8,,,Overall Response Rate,3581.0,3581.0,,,0.0,,,,,,,,2.33,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
8844.0,FLT3,FLT3_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Sunitinib,,Recruiting,NCT02693535,TAPUR,ECD,2024Dec31,Expression confirmed,Yes,,2.0,10.1007/s11523-020-00752-8,,,Overall Response Rate,3581.0,3581.0,,,0.0,,,,,,,,2.33,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
8845.0,FLT3,FLT3_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Sunitinib,,Recruiting,NCT02693535,TAPUR,ECD,2024Dec31,Expression confirmed,Yes,,2.0,10.1007/s11523-020-00752-8,,,Overall Response Rate,3581.0,3581.0,,,0.0,,,,,,,,2.33,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
8846.0,FLT3,FLT3_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Sunitinib,,Recruiting,NCT02693535,TAPUR,ECD,2024Dec31,Expression confirmed,Yes,,2.0,10.1007/s11523-020-00752-8,,,Overall Response Rate,3581.0,3581.0,,,0.0,,,,,,,,2.33,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
8847.0,FLT3,FLT3_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Sunitinib,,Recruiting,NCT02693535,TAPUR,ECD,2024Dec31,Expression confirmed,Yes,,2.0,10.1007/s11523-020-00752-8,,,Overall Response Rate,3581.0,3581.0,,,0.0,,,,,,,,2.33,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
8848.0,FLT3,FLT3_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Sunitinib,,Recruiting,NCT02693535,TAPUR,ECD,2024Dec31,Expression confirmed,Yes,,2.0,10.1007/s11523-020-00752-8,,,Overall Response Rate,3581.0,3581.0,,,0.0,,,,,,,,2.33,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
8849.0,FLT3,FLT3_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Sunitinib,,Recruiting,NCT02693535,TAPUR,ECD,2024Dec31,Expression confirmed,Yes,,2.0,10.1007/s11523-020-00752-8,,,Overall Response Rate,3581.0,3581.0,,,0.0,,,,,,,,2.33,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
8850.0,FLT3,FLT3_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Sunitinib,,Recruiting,NCT02693535,TAPUR,ECD,2024Dec31,Expression confirmed,Yes,,2.0,10.1007/s11523-020-00752-8,,,Overall Response Rate,3581.0,3581.0,,,0.0,,,,,,,,2.33,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
8851.0,FLT3,FLT3_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Sunitinib,,Recruiting,NCT02693535,TAPUR,ECD,2024Dec31,Expression confirmed,Yes,,2.0,10.1007/s11523-020-00752-8,,,Overall Response Rate,3581.0,3581.0,,,0.0,,,,,,,,2.33,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
8852.0,FLT3,FLT3_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Sunitinib,,Recruiting,NCT02693535,TAPUR,ECD,2024Dec31,Expression confirmed,Yes,,2.0,10.1007/s11523-020-00752-8,,,Overall Response Rate,3581.0,3581.0,,,0.0,,,,,,,,2.33,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
8853.0,FLT3,FLT3_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Sunitinib,,Recruiting,NCT02693535,TAPUR,ECD,2024Dec31,Expression confirmed,Yes,,2.0,10.1007/s11523-020-00752-8,,,Overall Response Rate,3581.0,3581.0,,,0.0,,,,,,,,2.33,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
8854.0,FLT3,FLT3_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3.0,Phase 2,Sunitinib,,Recruiting,NCT02693535,TAPUR,ECD,2024Dec31,Expression confirmed,Yes,,2.0,10.1007/s11523-020-00752-8,,,Overall Response Rate,3581.0,3581.0,,,0.0,,,,,,,,2.33,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO28864826,2022Nov28,COSO28864826,large_intestine,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
